CN113943308A - 一种三环嘧啶类衍生物及用途 - Google Patents
一种三环嘧啶类衍生物及用途 Download PDFInfo
- Publication number
- CN113943308A CN113943308A CN202111496956.1A CN202111496956A CN113943308A CN 113943308 A CN113943308 A CN 113943308A CN 202111496956 A CN202111496956 A CN 202111496956A CN 113943308 A CN113943308 A CN 113943308A
- Authority
- CN
- China
- Prior art keywords
- compound
- pyrimidin
- furo
- pyrido
- tetrahydro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003230 pyrimidines Chemical class 0.000 title claims description 5
- 150000001875 compounds Chemical class 0.000 claims abstract description 183
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 29
- 206010006187 Breast cancer Diseases 0.000 claims abstract description 12
- 208000026310 Breast neoplasm Diseases 0.000 claims abstract description 12
- 206010008342 Cervix carcinoma Diseases 0.000 claims abstract description 12
- 206010009944 Colon cancer Diseases 0.000 claims abstract description 12
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims abstract description 12
- 201000010881 cervical cancer Diseases 0.000 claims abstract description 12
- 208000029742 colonic neoplasm Diseases 0.000 claims abstract description 12
- -1 (E) -N- (4-chlorophenyl) -2- (4-fluorophenyl) -6,7,8, 9-tetrahydro-4H-furo [2,3-d ] pyrido [1,2-a ] pyrimidine-4-imine Chemical compound 0.000 claims description 56
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 claims description 50
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 24
- OYRRZWATULMEPF-UHFFFAOYSA-N pyrimidin-4-amine Chemical compound NC1=CC=NC=N1 OYRRZWATULMEPF-UHFFFAOYSA-N 0.000 claims description 20
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 10
- 239000002246 antineoplastic agent Substances 0.000 claims description 5
- 229940041181 antineoplastic drug Drugs 0.000 claims description 5
- VTGOHKSTWXHQJK-UHFFFAOYSA-N pyrimidin-2-ol Chemical class OC1=NC=CC=N1 VTGOHKSTWXHQJK-UHFFFAOYSA-N 0.000 claims description 4
- KWEIVHXNPOKLPG-SFQUDFHCSA-N (10E)-10-[(3,4-dimethoxyphenyl)methylidene]-5-(4-fluorophenyl)-6-oxa-1,8-diazatricyclo[7.4.0.03,7]trideca-3(7),4,8-trien-2-one Chemical compound COC(C=CC(/C=C(\CCCN12)/C1=NC(OC(C(C=C1)=CC=C1F)=C1)=C1C2=O)=C1)=C1OC KWEIVHXNPOKLPG-SFQUDFHCSA-N 0.000 claims description 2
- XUIZVIUTTKBKSQ-NJNXFGOHSA-N BrC(C=C1)=CC=C1C1=CC(/C(\N(CCCC2)C2=N2)=N\C(C=C3)=CC=C3Br)=C2O1 Chemical compound BrC(C=C1)=CC=C1C1=CC(/C(\N(CCCC2)C2=N2)=N\C(C=C3)=CC=C3Br)=C2O1 XUIZVIUTTKBKSQ-NJNXFGOHSA-N 0.000 claims description 2
- HZHBLLBWTPULDM-DARPEHSRSA-N BrC(C=C1)=CC=C1C1=CC(/C(\N(CCCC2)C2=N2)=N\C3=CC=CC=C3)=C2O1 Chemical compound BrC(C=C1)=CC=C1C1=CC(/C(\N(CCCC2)C2=N2)=N\C3=CC=CC=C3)=C2O1 HZHBLLBWTPULDM-DARPEHSRSA-N 0.000 claims description 2
- BADFZJKNZHYHOI-NJNXFGOHSA-N FC(C=C1)=CC=C1C1=CC(/C(\N(CCCC2)C2=N2)=N\C(C=C3)=CC=C3F)=C2O1 Chemical compound FC(C=C1)=CC=C1C1=CC(/C(\N(CCCC2)C2=N2)=N\C(C=C3)=CC=C3F)=C2O1 BADFZJKNZHYHOI-NJNXFGOHSA-N 0.000 claims description 2
- ZGMVAECGEFGYRA-DARPEHSRSA-N FC(C=C1)=CC=C1C1=CC(/C(\N(CCCC2)C2=N2)=N\C3=CC=CC=C3)=C2O1 Chemical compound FC(C=C1)=CC=C1C1=CC(/C(\N(CCCC2)C2=N2)=N\C3=CC=CC=C3)=C2O1 ZGMVAECGEFGYRA-DARPEHSRSA-N 0.000 claims description 2
- MBMQEIFVQACCCH-QBODLPLBSA-N zearalenone Chemical compound O=C1O[C@@H](C)CCCC(=O)CCC\C=C\C2=CC(O)=CC(O)=C21 MBMQEIFVQACCCH-QBODLPLBSA-N 0.000 claims description 2
- 238000006243 chemical reaction Methods 0.000 abstract description 60
- 150000008318 pyrimidones Chemical class 0.000 abstract description 9
- 238000009833 condensation Methods 0.000 abstract description 2
- 230000005494 condensation Effects 0.000 abstract description 2
- 230000026030 halogenation Effects 0.000 abstract description 2
- 238000005658 halogenation reaction Methods 0.000 abstract description 2
- 239000002994 raw material Substances 0.000 abstract description 2
- 239000013641 positive control Substances 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 167
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 153
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 99
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 78
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 44
- 238000002360 preparation method Methods 0.000 description 41
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 40
- 239000003208 petroleum Substances 0.000 description 40
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 39
- 239000000741 silica gel Substances 0.000 description 39
- 229910002027 silica gel Inorganic materials 0.000 description 39
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 36
- 238000005160 1H NMR spectroscopy Methods 0.000 description 36
- 239000007787 solid Substances 0.000 description 36
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 33
- IWTFOFMTUOBLHG-UHFFFAOYSA-N 2-methoxypyridine Chemical compound COC1=CC=CC=N1 IWTFOFMTUOBLHG-UHFFFAOYSA-N 0.000 description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 22
- 239000011261 inert gas Substances 0.000 description 22
- 239000000243 solution Substances 0.000 description 19
- 238000001035 drying Methods 0.000 description 16
- 230000000694 effects Effects 0.000 description 16
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 15
- 238000010438 heat treatment Methods 0.000 description 13
- AOMVWOWKZNPIAB-UHFFFAOYSA-N O=C1N(CCCC2)C2=NC2=C1C=C(C(C=C1)=CC=C1F)O2 Chemical compound O=C1N(CCCC2)C2=NC2=C1C=C(C(C=C1)=CC=C1F)O2 AOMVWOWKZNPIAB-UHFFFAOYSA-N 0.000 description 12
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical class [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 12
- DHLWGISGKKAIJD-UHFFFAOYSA-N O=C1N(CCCC2)C2=NC2=C1C=C(C(C=C1)=CC=C1Br)O2 Chemical compound O=C1N(CCCC2)C2=NC2=C1C=C(C(C=C1)=CC=C1Br)O2 DHLWGISGKKAIJD-UHFFFAOYSA-N 0.000 description 11
- 238000010992 reflux Methods 0.000 description 11
- GJCZSBFZPFUQHR-UHFFFAOYSA-N 5-(4-chlorophenyl)-6-methyl-1,6,8-triazatricyclo[7.4.0.03,7]trideca-3(7),4,8-trien-2-one Chemical compound CN(C(C(C=C1)=CC=C1Cl)=C1)C(N=C2N3CCCC2)=C1C3=O GJCZSBFZPFUQHR-UHFFFAOYSA-N 0.000 description 10
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N N-phenyl amine Natural products NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 10
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 10
- UHOVQNZJYSORNB-MZWXYZOWSA-N benzene-d6 Chemical compound [2H]C1=C([2H])C([2H])=C([2H])C([2H])=C1[2H] UHOVQNZJYSORNB-MZWXYZOWSA-N 0.000 description 9
- 238000010828 elution Methods 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- GLZXFITXXAMCRJ-UHFFFAOYSA-N azepin-4-one Chemical compound O=C1C=CC=NC=C1 GLZXFITXXAMCRJ-UHFFFAOYSA-N 0.000 description 7
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzenecarboxaldehyde Natural products O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 7
- 238000000605 extraction Methods 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- WJUFSDZVCOTFON-UHFFFAOYSA-N veratraldehyde Chemical compound COC1=CC=C(C=O)C=C1OC WJUFSDZVCOTFON-UHFFFAOYSA-N 0.000 description 6
- 239000003814 drug Substances 0.000 description 5
- VFZRZRDOXPRTSC-UHFFFAOYSA-N 3,5-Dimethoxybenzaldehyde Chemical compound COC1=CC(OC)=CC(C=O)=C1 VFZRZRDOXPRTSC-UHFFFAOYSA-N 0.000 description 4
- WMPDAIZRQDCGFH-UHFFFAOYSA-N 3-methoxybenzaldehyde Chemical compound COC1=CC=CC(C=O)=C1 WMPDAIZRQDCGFH-UHFFFAOYSA-N 0.000 description 4
- WDFQBORIUYODSI-UHFFFAOYSA-N 4-bromoaniline Chemical compound NC1=CC=C(Br)C=C1 WDFQBORIUYODSI-UHFFFAOYSA-N 0.000 description 4
- QSNSCYSYFYORTR-UHFFFAOYSA-N 4-chloroaniline Chemical compound NC1=CC=C(Cl)C=C1 QSNSCYSYFYORTR-UHFFFAOYSA-N 0.000 description 4
- KRZCOLNOCZKSDF-UHFFFAOYSA-N 4-fluoroaniline Chemical compound NC1=CC=C(F)C=C1 KRZCOLNOCZKSDF-UHFFFAOYSA-N 0.000 description 4
- ODGIMMLDVSWADK-UHFFFAOYSA-N 4-trifluoromethylaniline Chemical compound NC1=CC=C(C(F)(F)F)C=C1 ODGIMMLDVSWADK-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 4
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 4
- LQZMLBORDGWNPD-UHFFFAOYSA-N N-iodosuccinimide Chemical compound IN1C(=O)CCC1=O LQZMLBORDGWNPD-UHFFFAOYSA-N 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- OKPQNSHKOFNQBV-UHFFFAOYSA-N pyrido[1,2-a]pyrimidin-4-imine Chemical compound C1=CC=CN2C(=N)C=CN=C21 OKPQNSHKOFNQBV-UHFFFAOYSA-N 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- OUPMUGIXWNVDSN-UHFFFAOYSA-N 2-[hydroxy-(1-oxido-4-oxoquinoxalin-4-ium-2-yl)methyl]-4-methoxyphenol Chemical compound COC1=CC=C(O)C(C(O)C=2N(C3=CC=CC=C3[N+](=O)C=2)[O-])=C1 OUPMUGIXWNVDSN-UHFFFAOYSA-N 0.000 description 2
- 229910014263 BrF3 Inorganic materials 0.000 description 2
- XCHARIIIZLLEBL-UHFFFAOYSA-N Medicagenic acid 3-O-beta-D-glucoside Chemical compound C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C(O)=O)C)(C)C1=CCC2C3(C)CC(O)C4OC1OC(CO)C(O)C(O)C1O XCHARIIIZLLEBL-UHFFFAOYSA-N 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- WHRZCXAVMTUTDD-UHFFFAOYSA-N 1h-furo[2,3-d]pyrimidin-2-one Chemical class N1C(=O)N=C2OC=CC2=C1 WHRZCXAVMTUTDD-UHFFFAOYSA-N 0.000 description 1
- DNCYBUMDUBHIJZ-UHFFFAOYSA-N 1h-pyrimidin-6-one Chemical compound O=C1C=CN=CN1 DNCYBUMDUBHIJZ-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 208000025721 COVID-19 Diseases 0.000 description 1
- 229910020323 ClF3 Inorganic materials 0.000 description 1
- 238000003512 Claisen condensation reaction Methods 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 239000002262 Schiff base Substances 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 229940125810 compound 20 Drugs 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- SRCZQMGIVIYBBJ-UHFFFAOYSA-N ethoxyethane;ethyl acetate Chemical compound CCOCC.CCOC(C)=O SRCZQMGIVIYBBJ-UHFFFAOYSA-N 0.000 description 1
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- NYJWYCAHJRGKMI-UHFFFAOYSA-N pyrido[1,2-a]pyrimidin-4-one Chemical compound C1=CC=CN2C(=O)C=CN=C21 NYJWYCAHJRGKMI-UHFFFAOYSA-N 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- SRBUGYKMBLUTIS-UHFFFAOYSA-N pyrrolo[2,3-d]pyrimidin-2-one Chemical compound O=C1N=CC2=CC=NC2=N1 SRBUGYKMBLUTIS-UHFFFAOYSA-N 0.000 description 1
- RWWYLEGWBNMMLJ-YSOARWBDSA-N remdesivir Chemical compound NC1=NC=NN2C1=CC=C2[C@]1([C@@H]([C@@H]([C@H](O1)CO[P@](=O)(OC1=CC=CC=C1)N[C@H](C(=O)OCC(CC)CC)C)O)O)C#N RWWYLEGWBNMMLJ-YSOARWBDSA-N 0.000 description 1
- RWWYLEGWBNMMLJ-MEUHYHILSA-N remdesivir Drugs C([C@@H]1[C@H]([C@@H](O)[C@@](C#N)(O1)C=1N2N=CN=C(N)C2=CC=1)O)OP(=O)(N[C@@H](C)C(=O)OCC(CC)CC)OC1=CC=CC=C1 RWWYLEGWBNMMLJ-MEUHYHILSA-N 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
本发明涉及一种三环嘧啶酮类衍生物及用途。该类衍生物以A1、A2、B1、B2、C1、C2、D1、D2等六个化合物为初始原料,通过缩合和卤代等反应得到相应的E1‑E10、F1‑F10、G1‑G10、H1‑H6 36个衍生物。以DOX为阳性对照;考察了这36种化合物对HeLa宫颈癌细胞、MCF‑7乳腺癌细胞、HT‑29人结肠癌细胞的抑制活性,结果显示:有7个化合物对HeLa宫颈癌细胞有抑制活性;有2个化合物对MCF‑7乳腺癌细胞有抑制活性;有10个化合物对HT‑29人结肠癌细胞有抑制活性。其中,E2、E3、F3、F5、H1、H5、H6对HeLa宫颈癌细胞有抑制活性;H1、H2对MCF‑7乳腺癌细胞有抑制活性;E2、E3、F5、G1、G6、G7、H1、H3、H5、H6对HT‑29人结肠癌细胞有抑制活性。
Description
技术领域
本发明涉及一种新型三环嘧啶酮类衍生物在抗肿瘤药物中的用途,该类衍生物经细胞活性筛选结果表明:有7个化合物对HeLa宫颈癌细胞有抑制活性;有2个化合物对MCF-7乳腺癌细胞有抑制活性;有10个化合物对HT-29人结肠癌细胞有抑制活性。
背景技术
杂环化合物是一类重要的化合物,具有良好生物活性,在药物化学中占据着非常重要的地位[1-3]。从天然动、植物中寻找低毒、疗效高的抗癌活性成分的报道较少,所以,化学合成的抗癌药仍是近年国内、外科学工作者研究的热点之一。嘧啶环类化合物在抗肿瘤[6-8]、抗病毒[9-11]等方面有着非常显著的抑制活性,比如,最近上市的有关治疗COVID-19的药物有核苷类药物瑞德西韦[12]等。因此,我们期望发现具有广谱、高效、低毒的化合物。寻找新医药等先导化合物具有较大的理论和应用价值。
近期,本课题组在前期工作的基础上,挑选出抗肿瘤活性较好的化合物进行结构修饰合成了36个嘧啶类化合物,并进一步研究了这些化合物在抗肿瘤药物中的用途,活性筛选结果表明:有7个化合物对HeLa宫颈癌细胞有抑制活性;有2个化合物对MCF-7乳腺癌细胞有抑制活性;有10个化合物对HT-29人结肠癌细胞有抑制活性。
参考文献:
[1]Huang,J.M,Chen,R.Y.Studies of a-Thiocarbonyl Phosphonic AcidDerivative Quinazolone Analogues Containing Phosphorus[J].Chemical Journal ofChinses Universities.2000,8(21),1216-1220.
[2]Bai,Z.S.;Wang,D.X.Heterocyclic Compounds Genetic Engineering andPesticides in 21 Century[J].Pesticides.1998,37(6),2-6.
[3]Zhou,J;Qiu,H.G.;Feng,K.S.;Chen,R.Y.Synthesis and HerbicidalActivity of l-Aryl-2-phenyl-3-methyl-3-isopropyl-1,4,2-diazaphosp-holidin-5-one-2-oxides[J].Chemical Journal of Chinses Universities.1999,20(7),1058-1062.
[4]Gupta,P.K.;Daunert,S.;Nassiri,M.R.;;Wotring,L.L.;Drach,J.C.;Townsend,L.B.,Synthesis,cytotoxicity,and antiviral activity of some acyclicanalogs of the pyrrolo[2,3-d]pyrimidine nucleoside antibiotics tubercidin,toyocamycin,and sangivamycin.Journal of Medicinal Chemistry.1989,32(2),402-408.
[5]Bennett,S.M.;Nguyen Ba,N.;Ogilvie,K.K.,Synthesis and antiviralactivity of some acyclic and C-acyclic pyrrolo[2,3-d]pyrimidine nucleosideanalogs.Journal of Medicinal Chemistry.1990,33(8),2162-2173.
[6]Renau,T.E.;Kennedy,C.;Ptak,R.G.;Breitenbach,J.M.;Drach,J.C.;Townsend,L.B.,Synthesis of Non-nucleoside Analogs of Toyocamycin,Sangivamycin,and Thiosangivamycin:The Effect of Certain 4-and 4,6-Substituents on the Antiviral Activity of Pyrrolo[2,3-d]pyrimidines.Journalof Medicinal Chemistry.1996,39(18),3470-3476.
[7]Miwa,T.;Hitaka,T.;Akimoto,H.;Nomura,H.,Novel pyrrolo[2,3-d]pyrimidine antifolates:synthesis and antitumor activities.Journal ofMedicinal Chemistry.1991,34(2),555-560.
[8]Gangjee,A.;Zeng,Y.;McGuire,J.J.;Mehraein,F.;Kisliuk,R.L.,Synthesisof Classical,Three-Carbon-Bridged 5-Substituted Furo[2,3-d]pyrimidine and 6-Substituted Pyrrolo[2,3-d]pyrimidine Analogues as Antifolates.Journal ofMedicinal Chemistry.2004,47(27),6893-6901.
[9]Wang,Y.;Cherian,C.;Orr,S.;Mitchell-Ryan,S.;;Hou,Z.;Raghavan,S.;Matherly,L.H.;Gangjee,A.,Tumor-targeting with novel non-benzoyl 6-substitutedstraight chain pyrrolo[2,3-d]pyrimidine antifolates via cellular uptake byfolate receptor alpha and inhibition of de novo purine nucleotidebiosynthesis.Journal of Medicinal Chemistry.2013,56(21),8684-95.
[10]Wang,M.;Zhang,L.;Huo,X.;Zhang,Z.;Yuan,Q.;Li,P.;Chen,J.;Zou,Y.;Wu,Z.;Zhang,W.,Catalytic Asymmetric Synthesis of the anti-COVID-19DrugRemdesivir.Angew Chem Int Ed Engl.2020,59(47),20814-20819.
本发明在国内外有关专利、文献的综合分析的基础上,对新型三环吡咯并[2,3-d]嘧啶酮和三环呋喃并[2,3-d]嘧啶酮类化合物进行简单的改造和修饰,将含不同取代基的苯基引入到新型三环嘧啶酮类化合物分子中,以期望提高其成药性,并研究了这些化合物对HeLa宫颈癌细胞、MCF-7乳腺癌细胞、HT-29人结肠癌细胞的抑制活性,以期发现疗效显著、靶点明确的抗肿瘤活性的候选药物。
发明内容
本发明的目的在于,提供一种三环嘧啶酮类衍生物及用途。该类衍生物以A1、A2、B1、B2、C1、C2、D1、D2等六个化合物为初始原料,通过缩合和卤代等反应得到相应的E1-E10、F1-F10、G1-G10、H1-H6等36个衍生物。之后,还考察了这36种化合物对HeLa宫颈癌细胞、MCF-7乳腺癌细胞、HT-29人结肠癌细胞的抑制活性,结果显示:有7个化合物对HeLa宫颈癌细胞有抑制活性;有2个化合物对MCF-7乳腺癌细胞有抑制活性;有10个化合物对HT-29人结肠癌细胞有抑制活性。其中,E2、E3、F3、F5、H1、H5、H6对HeLa宫颈癌细胞有抑制活性;H1、H2对MCF-7乳腺癌细胞有抑制活性;E2、E3、F5、G1、G6、G7、H1、H3、H5、H6对HT-29人结肠癌细胞有抑制活性。
本发明所述的一种三环嘧啶类衍生物,该类衍生物的结构如下所示:
其中
化合物E-1为(E)-2-(4-氟苯基)-N-苯基-6,7,8,9-四氢-4H-呋喃并[2,3-d]吡啶并[1,2-a]嘧啶-4-亚胺;
化合物E-2为(E)-N,2-双(4-氟苯基)-6,7,8,9-四氢-4H-呋喃并[2,3-d]吡啶并[1,2-a]嘧啶-4-亚胺;
化合物E-3为(E)-N-(4-氯苯基)-2-(4-氟苯基)-6,7,8,9-四氢-4H-呋喃并[2,3-d]吡啶并[1,2-a]嘧啶-4-亚胺;
化合物E-4为(E)-N-(4-溴苯基)-2-(4-氟苯基)-6,7,8,9-四氢-4H-呋喃并[2,3-d]吡啶并[1,2-a]嘧啶-4-亚胺;
化合物E-5为(E)-2-(4-氟苯基)-N-(4-(三氟甲基)苯基)-6,7,8,9-四氢-4H-呋喃并[2,3-d]吡啶并[1,2-a]嘧啶-4-亚胺;
化合物E-6为(E)-2-(4-溴苯基)-N-苯基-6,7,8,9-四氢-4H-呋喃并[2,3-d]吡啶并[1,2-a]嘧啶-4-亚胺;
化合物E-7为(E)-2-(4-溴苯基)-N-(4-氟苯基)-6,7,8,9-四氢-4H-呋喃并[2,3-d]吡啶并[1,2-a]嘧啶-4-亚胺;
化合物E-8为(E)-2-(4-溴苯基)-N-(4-氯苯基)-6,7,8,9-四氢-4H-呋喃并[2,3-d]吡啶并[1,2-a]嘧啶-4-亚胺;
化合物E-9为(E)-N,2-双(4-溴苯基)-6,7,8,9-四氢-4H-呋喃并[2,3-d]吡啶并[1,2-a]嘧啶-4-亚胺;
化合物E-10为(E)-2-(4-溴苯基)-N-(4-(三氟甲基)苯基)-6,7,8,9-四氢-4H-呋喃并[2,3-d]吡啶并[1,2-a]嘧啶-4-亚胺;
化合物F-1为(E)-9-亚苄基-2-(4-氟苯基)-6,7,8,9-四氢-4H-呋喃并[2,3-d]吡啶并[1,2-a]嘧啶-4-酮;
化合物F-2为(E)-2-(4-氟苯基)-9-(3-甲氧基亚苄基)-6,7,8,9-四氢-4H-呋喃并[2,3-d]吡啶并[1,2-a]嘧啶-4-酮;
化合物F-3为(E)-9-(3,4-二甲氧基亚苄基)-2-(4-氟苯基)-6,7,8,9-四氢-4H-呋喃并[2,3-d]吡啶并[1,2-a]嘧啶-4-酮;
化合物F-4为(E)-9-(3,5-二甲氧基亚苄基)-2-(4-氟苯基)-6,7,8,9-四氢-4H-呋喃并[2,3-d]吡啶并[1,2-a]嘧啶-4-酮;
化合物F-5为(E)-2-(4-氟苯基)-9-(3,4,5-三甲氧基亚苄基)-6,7,8,9-四氢-4H-呋喃并[2,3-d]吡啶并[1,2-a]嘧啶-4-酮;
化合物F-6为(E)-9-亚苄基-2-(4-溴苯基)-6,7,8,9-四氢-4H-呋喃并[2,3-d]吡啶并[1,2-a]嘧啶-4-酮;
化合物F-7为(E)-2-(4-溴苯基)-9-(3-甲氧基亚苄基)-6,7,8,9-四氢-4H-呋喃并[2,3-d]吡啶并[1,2-a]嘧啶-4-酮;
化合物F-8为(E)-2-(4-溴苯基)-9-(3,4-二甲氧基亚苄基)-6,7,8,9-四氢-4H-呋喃并[2,3-d]吡啶并[1,2-a]嘧啶-4-酮;
化合物F-9为(E)-2-(4-溴苯基)-9-(3,5-二甲氧基亚苄基)-6,7,8,9-四氢-4H-呋喃并[2,3-d]吡啶并[1,2-a]嘧啶-4-酮;
化合物F-10为(E)-2-(4-溴苯基)-9-(3,4,5-三甲氧基亚苄基)-6,7,8,9-四氢-4H-呋喃并[2,3-d]吡啶并[1,2-a]嘧啶-4-酮;
化合物G-1为(E)-2-(4-氯苯基)-1-甲基-N-苯基-6,7,8,9-四氢吡啶并[1,2-a]吡咯并[2,3-d]嘧啶-4(1H)-亚胺;
化合物G-2为(E)-2-(4-氯苯基)-N-(4-氟苯基)-1-甲基-6,7,8,9-四氢吡啶并[1,2-a]吡咯并[2,3-d]嘧啶-4(1H)-亚胺;
化合物G-3为(E)-N,2-双(4-氯苯基)-1-甲基-6,7,8,9-四氢吡啶并[1,2-a]吡咯并[2,3-d]嘧啶-4(1H)-亚胺;
化合物G-4为(E)-N-(4-溴苯基)-2-(4-氯苯基)-1-甲基-6,7,8,9-四氢吡啶并[1,2-a]吡咯并[2,3-d]嘧啶-4(1H)-亚胺;
化合物G-5为(E)-2-(4-氯苯基)-1-甲基-N-(4-(三氟甲基)苯基)-6,7,8,9-四氢吡啶并[1,2-a]吡咯并[2,3-d]嘧啶-4(1H)-亚胺;
化合物G-6为(E)-2-(4-溴苯基)-1-甲基-N-苯基-1,6,7,8,9,10-六氢-4H-吡咯并[2',3':4,5]嘧啶并[1,2-a]氮杂-4-亚胺;
化合物G-7为(E)-2-(4-溴苯基)-N-(4-氟苯基)-1-甲基-1,6,7,8,9,10-六氢-4H-吡咯并[2',3':4,5]嘧啶并[1,2-a]氮杂-4-亚胺;
化合物G-8为(E)-2-(4-溴苯基)-N-(4-氯苯基)-1-甲基-1,6,7,8,9,10-六氢-4H-吡咯并[2',3':4,5]嘧啶并[1,2-a]氮杂-4-亚胺;
化合物G-9为(E)-N,2-双(4-溴苯基)-1-甲基-1,6,7,8,9,10-六氢-4H-吡咯并[2',3':4,5]嘧啶并[1,2-a]氮杂-4-亚胺;
化合物G-10为(E)-2-(4-溴苯基)-1-甲基-N-(4-(三氟甲基)苯基)-1,6,7,8,9,10-六氢-4H-吡咯并[2',3':4,5]嘧啶并[1,2-a]氮杂-4-亚胺;
化合物H-1为3-氯-2-(4-氯苯基)-1-甲基-6,7,8,9-四氢吡啶并[1,2-a]吡咯并[2,3-d]嘧啶-4(1H)-酮;
化合物H-2为3-溴-2-(4-氯苯基)-1-甲基-6,7,8,9-四氢吡啶并[1,2-a]吡咯并[2,3-d]嘧啶-4(1H)-酮;
化合物H-3为2-(4-氯苯基)-3-碘-1-甲基-6,7,8,9-四氢吡啶并[1,2-a]吡咯并[2,3-d]嘧啶-4(1H)-酮;
化合物H-4为2-(4-溴苯基)-3-氯-1-甲基-1,6,7,8,9,10-六氢-4H-吡咯并[2',3':4,5]嘧啶并[1,2-a]氮杂-4-酮;
化合物H-5为3-溴-2-(4-溴苯基)-1-甲基-1,6,7,8,9,10-六氢-4H-吡咯并[2',3':4,5]嘧啶并[1,2-a]氮杂-4-酮;
化合物H-6为2-(4-溴苯基)-3-碘-1-甲基-1,6,7,8,9,10-六氢-4H-吡咯并[2',3':4,5]嘧啶并[1,2-a]氮杂-4-酮。
所述的三环嘧啶酮类衍生物中的E1-E10、F1-F10、G1-G10和H1-H6在抗肿瘤药物中的用途。
所述三环嘧啶酮类衍生物中的E2、E3、F3、F5、H1、H5和H6对HeLa宫颈癌细胞有抑制活性;H1和H2对MCF-7乳腺癌细胞有抑制活性;E2、E3、F5、G1、G6、G7、H1、H3、H5和H6对HT-29人结肠癌细胞有抑制活性。
本发明所述的一种三环嘧啶酮类衍生物,其合成路线如下:
本发明所述的三环嘧啶酮类衍生物及用途,其中三环嘧啶酮类衍生物的制备方法,按下列步骤进行:
化合物E1-E10的制备:
在100mL两口瓶中,加入0.50mmol的2-(4-氟苯基)-6,7,8,9-四氢-4H-呋喃并[2,3-d]吡啶并[1,2-a]嘧啶-4-酮或2-(4-溴苯基)-6,7,8,9-四氢-4H-呋喃并[2,3-d]吡啶并[1,2-a]嘧啶-4-酮,再加入30mL无水二氯甲烷,并进行惰性气体保护,在温度0℃条件下,滴加0.55mmol 2-甲氧基吡啶和1.0mmol三氟甲磺酸酐,30min后加入1.0mmol苯胺类化合物,在温度0℃条件下保持10min,转移至室温继续反应1.5小时,加入饱和碳酸氢钠,用二氯甲烷萃取,无水硫酸钠干燥,浓缩,用200-300目的硅胶,体积比4:1的石油醚:乙酸乙酯进行洗脱,分别得到化合物E1-E10;
化合物F1-F10的制备:
在100mL两口瓶中,加入0.50mmol的2-(4-氟苯基)-6,7,8,9-四氢-4H-呋喃并[2,3-d]吡啶并[1,2-a]嘧啶-4-酮或2-(4-溴苯基)-6,7,8,9-四氢-4H-呋喃并[2,3-d]吡啶并[1,2-a]嘧啶-4-酮,加入2.50mmol苯甲醛类化合物,加入2.50mmol氢氧化钠,再加入30mL乙醇,加热回流,通过TLC监测反应,直至反应完成,浓缩反应液,用饱和食盐水洗涤,无水硫酸钠干燥,用乙酸乙酯萃取,再浓缩,用200-300目的硅胶,体积比4:1的石油醚:乙酸乙酯进行洗脱,分别得到化合物F1-F10;
化合物G1-G10的制备:
在100mL两口瓶中,加入0.50mmol的2-(4-氯苯基)-1-甲基-6,7,8,9-四氢吡啶并[1,2-a]吡咯并[2,3-d]嘧啶-4(1H)-酮或2-(4-溴苯基)-1-甲基-1,6,7,8,9,10-六氢-4H-吡咯并[2',3':4,5]嘧啶并[1,2-a]氮杂-4-酮,再加入30mL无水二氯甲烷,并进行惰性气体保护,在温度0℃条件下,滴加0.55mmol 2-甲氧基吡啶和1.0mmol三氟甲磺酸酐,30min后加入1.0mmol苯胺类化合物,在温度0℃条件下保持10min,在升至室温继续反应1.5小时,加入饱和碳酸氢钠,用二氯甲烷萃取,无水硫酸钠干燥,浓缩,用200-300目的硅胶,体积比4:1的石油醚:乙酸乙酯进行洗脱,分别得到化合物G1-G10;
化合物H1-H6的制备:
在50mL单口瓶中,加入0.50mmol的2-(4-氯苯基)-1-甲基-6,7,8,9-四氢吡啶并[1,2-a]吡咯并[2,3-d]嘧啶-4(1H)-酮或2-(4-溴苯基)-1-甲基-1,6,7,8,9,10-六氢-4H-吡咯并[2',3':4,5]嘧啶并[1,2-a]氮杂-4-酮,加入10mL二氯甲烷,再加入0.55mmol N-卤代琥珀酰亚胺,室温或加热,通过TLC监测反应,直至反应完成,浓缩反应液,用饱和食盐水洗涤,无水硫酸钠干燥,用乙酸乙酯萃取,再浓缩,用200-300目的硅胶,体积比2:1的石油醚:乙酸乙酯进行洗脱,分别得到化合物H1-H6。
具体实施方式
依据实施例对本发明进一步说明,但本发明不仅限于这些实施例;
试剂:除原料A、B、C、D之外所有试剂均为市售的分析纯;
实施例1
化合物E1(E)-2-(4-氟苯基)-N-苯基-6,7,8,9-四氢-4H-呋喃并[2,3-d]吡啶并[1,2-a]嘧啶-4-亚胺的制备:
在100mL两口瓶中,加入145mg,0.50mmol的2-(4-氟苯基)-6,7,8,9-四氢-4H-呋喃并[2,3-d]吡啶并[1,2-a]嘧啶-4-酮,再加入30mL无水二氯甲烷,并进行惰性气体保护,在温度0℃条件下,滴加58μL,0.55mmol 2-甲氧基吡啶,滴加168μL,1.0mmo)三氟甲磺酸酐,30min后加(91μL,1.0mmo)苯胺,10min后,升至室温继续反应1.5小时,加入饱和碳酸氢钠,用二氯甲烷萃取,无水硫酸钠干燥,浓缩,用200-300目的硅胶,体积比4:1的石油醚:乙酸乙酯进行洗脱,得到化合物E1(E)-2-(4-氟苯基)-N-苯基-6,7,8,9-四氢-4H-呋喃并[2,3-d]吡啶并[1,2-a]嘧啶-4-亚胺,产率:99%,黄色固体,m.p.229-230℃;
1H NMR(400MHz,Chloroform-d)δ7.45–7.38(m,2H),7.40–7.31(m,2H),7.14(t,J=7.4Hz,1H),7.03–6.96(m,2H),6.91(d,J=7.3Hz,2H),5.41(s,1H),4.13(t,J=6.2Hz,2H),2.98(t,J=6.7Hz,2H),2.06(p,J=6.1Hz,2H),1.95(p,J=6.5Hz,2H).13C NMR(101MHz,CDCl3)δ163.57,161.10,160.81,156.85,150.78,148.56,148.34,129.24,125.97,125.66,125.58,122.77,121.80,115.82,115.60,102.11,44.66,32.50,22.62,19.13.HRMS(ESI):calcd for C22H19FN3O[M+H]+:360.1512,found:360.1484。
实施例2
化合物E2(E)-N,2-双(4-氟苯基)-6,7,8,9-四氢-4H-呋喃并[2,3-d]吡啶并[1,2-a]嘧啶-4-亚胺的制备:
在100mL两口瓶中,加入145mg,0.50mmol的2-(4-氟苯基)-6,7,8,9-四氢-4H-呋喃并[2,3-d]吡啶并[1,2-a]嘧啶-4-酮,再加入30mL无水二氯甲烷,并进行惰性气体保护,在温度0℃条件下,滴加58μL,0.55mmol 2-甲氧基吡啶,滴加168μL,1.0mmol三氟甲磺酸酐,30min后加入111mg,1.0mmol 4-氟苯胺,10min后,升至室温继续反应1.5小时,加入饱和碳酸氢钠,用二氯甲烷萃取,无水硫酸钠干燥,浓缩,用200-300目的硅胶,体积比4:1的石油醚:乙酸乙酯进行洗脱,得到化合物E2(E)-N,2-双(4-氟苯基)-6,7,8,9-四氢-4H-呋喃并[2,3-d]吡啶并[1,2-a]嘧啶-4-亚胺,产率:99%,黄色固体,m.p.232-233℃;
1H NMR(400MHz,Chloroform-d)δ7.50–7.41(m,2H),7.11–6.98(m,4H),6.90–6.81(m,2H),5.50(s,1H),4.11(t,J=6.2Hz,2H),2.99(t,J=6.7Hz,2H),2.06(p,J=6.2Hz,2H),1.95(p,J=6.5Hz,2H).13C NMR(101MHz,CDCl3)δ163.67,161.21,160.90,160.28,157.89,156.90,149.04,148.57,125.75,125.67,122.86,122.78,115.94,115.90,115.72,115.69,102.11,101.77,44.73,32.50,22.61,19.09.HRMS(ESI):calcd for C22H18F2N3O[M+H]+:378.1418,found:360.1390。
实施例3
化合物E3(E)-N-(4-氯苯基)-2-(4-氟苯基)-6,7,8,9-四氢-4H-呋喃并[2,3-d]吡啶并[1,2-a]嘧啶-4-亚胺的制备:
在100mL两口瓶中,加入145mg,0.50mmol的2-(4-氟苯基)-6,7,8,9-四氢-4H-呋喃并[2,3-d]吡啶并[1,2-a]嘧啶-4-酮,再加入30mL无水二氯甲烷,并进行惰性气体保护,在温度0℃条件下,滴加58μL,0.55mmol 2-甲氧基吡啶,滴加168μL,1.0mmol三氟甲磺酸酐,30min后加入128mg,1.0mmol 4-氯苯胺,10min后,升至室温继续反应1.5小时,加入饱和碳酸氢钠,用二氯甲烷萃取,无水硫酸钠干燥,浓缩,用200-300目的硅胶,体积比4:1的石油醚:乙酸乙酯进行洗脱,得到化合物E3(E)-N-(4-氯苯基)-2-(4-氟苯基)-6,7,8,9-四氢-4H-呋喃并[2,3-d]吡啶并[1,2-a]嘧啶-4-亚胺,产率:99%,黄色固体,m.p.209-210℃;
1H NMR(400MHz,Chloroform-d)δ7.50–7.43(m,2H),7.34–7.29(m,2H),7.07–6.99(m,2H),6.88–6.82(m,2H),5.60(s,1H),4.10(t,J=6.2Hz,2H),2.99(t,J=6.7Hz,2H),2.06(p,J=6.8,6.2Hz,2H),1.95(p,J=6.5Hz,2H).13C NMR(101MHz,CDCl3)δ163.71,161.24,160.93,156.91,149.31,148.70,148.57,129.21,127.68,125.82,125.74,123.11,115.92,115.70,102.07,101.74,44.73,32.49,22.59,19.09.HRMS(ESI):calcd forC22H18ClFN3O[M+H]+:394.1122,found:394.1094。
实施例4
化合物E4(E)-N-(4-溴苯基)-2-(4-氟苯基)-6,7,8,9-四氢-4H-呋喃并[2,3-d]吡啶并[1,2-a]嘧啶-4-亚胺的制备:
在100mL两口瓶中,加入145mg,0.50mmol的2-(4-氟苯基)-6,7,8,9-四氢-4H-呋喃并[2,3-d]吡啶并[1,2-a]嘧啶-4-酮,再加入30mL无水二氯甲烷,并进行惰性气体保护,在温度0℃条件下,滴加58μL,0.55mmol 2-甲氧基吡啶,滴加168μL,1.0mmol三氟甲磺酸酐,30min后加入172mg,1.0mmol 4-溴苯胺,10min后,升至室温继续反应1.5小时,加入饱和碳酸氢钠,用二氯甲烷萃取,无水硫酸钠干燥,浓缩,用200-300目的硅胶,体积比4:1的石油醚:乙酸乙酯进行洗脱,得到化合物E4(E)-N-(4-溴苯基)-2-(4-氟苯基)-6,7,8,9-四氢-4H-呋喃并[2,3-d]吡啶并[1,2-a]嘧啶-4-亚胺,产率:99%,黄色固体,m.p.210-211℃;
1H NMR(400MHz,Chloroform-d)δ7.51–7.43(m,4H),7.07–7.00(m,2H),6.83–6.77(m,2H),5.61(s,1H),4.10(t,J=6.2Hz,2H),2.99(t,J=6.7Hz,2H),2.06(p,J=6.6,6.1Hz,2H),1.95(p,J=6.6Hz,2H).13C NMR(101MHz,CDCl3)δ163.72,161.25,160.96,156.92,149.75,148.75,148.47,132.15,125.85,125.76,123.62,115.93,115.71,115.24,102.07,101.72,44.76,32.49,22.59,19.08.HRMS(ESI):calcd for C22H18BrFN3O[M+H]+:438.0617,found:438.0585。
实施例5
化合物E5(E)-2-(4-氟苯基)-N-(4-(三氟甲基)苯基)-6,7,8,9-四氢-4H-呋喃并[2,3-d]吡啶并[1,2-a]嘧啶-4-亚胺的制备:
在100mL两口瓶中,加入145mg,0.50mmol的2-(4-氟苯基)-6,7,8,9-四氢-4H-呋喃并[2,3-d]吡啶并[1,2-a]嘧啶-4-酮,再加入30mL无水二氯甲烷,并进行惰性气体保护,在温度0℃条件下,滴加58μL,0.55mmol 2-甲氧基吡啶,滴加168μL,1.0mmol三氟甲磺酸酐,30min后加入126μL,1.0mmol4-三氟甲基苯胺,10min后,升至室温继续反应1.5小时,加入饱和碳酸氢钠,用二氯甲烷萃取,无水硫酸钠干燥,浓缩,用200-300目的硅胶,体积比4:1的石油醚:乙酸乙酯进行洗脱,得到化合物E5(E)-2-(4-氟苯基)-N-(4-(三氟甲基)苯基)-6,7,8,9-四氢-4H-呋喃并[2,3-d]吡啶并[1,2-a]嘧啶-4-亚胺,产率:75%,黄色固体,m.p.224-225℃;
1H NMR(400MHz,Chloroform-d)δ7.61(d,J=8.3Hz,2H),7.46–7.40(m,2H),7.06–6.97(m,4H),5.50(s,1H),4.13(t,J=6.2Hz,2H),3.01(t,J=6.7Hz,2H),2.08(p,J=6.6,6.1Hz,2H),1.96(p,J=6.7Hz,2H).13C NMR(101MHz,CDCl3)δ163.76,161.29,161.02,156.95,154.10,148.96,148.33,126.37,125.79,125.71,121.98,115.96,115.74,102.03,101.45,44.83,32.48,22.57,19.07.HRMS(ESI):calcd for C23H18F4N3O[M+H]+:428.1386,found:428.1354。
实施例6
化合物E6(E)-2-(4-溴苯基)-N-苯基-6,7,8,9-四氢-4H-呋喃并[2,3-d]吡啶并[1,2-a]嘧啶-4-亚胺的制备:
在100mL两口瓶中,加入173mg,0.50mmol的2-(4-溴苯基)-6,7,8,9-四氢-4H-呋喃并[2,3-d]吡啶并[1,2-a]嘧啶-4-酮,再加入30mL无水二氯甲烷,并进行惰性气体保护,在温度0℃条件下,滴加58μL,0.55mmol 2-甲氧基吡啶,滴加168μL,1.0mmol三氟甲磺酸酐,30min后加入91μL,1.0mmol苯胺,10min后,升至室温继续反应1.5小时,加入饱和碳酸氢钠,用二氯甲烷萃取,无水硫酸钠干燥,浓缩,用200-300目的硅胶,体积比4:1的石油醚:乙酸乙酯进行洗脱,得到化合物E6(E)-2-(4-溴苯基)-N-苯基-6,7,8,9-四氢-4H-呋喃并[2,3-d]吡啶并[1,2-a]嘧啶-4-亚胺,产率:99%,黄色固体,m.p.226-227℃;
1H NMR(400MHz,Chloroform-d)δ7.46–7.38(m,2H),7.36(t,J=7.7Hz,2H),7.34–7.26(m,3H),7.15(t,J=7.4Hz,1H),6.91(d,J=7.4Hz,2H),5.48(s,1H),4.14(t,J=6.2Hz,2H),2.99(t,J=6.7Hz,2H),2.11–2.02(m,2H),1.95(p,J=6.5Hz,2H).13C NMR(151MHz,CDCl3)δ161.04,157.22,150.66,148.56,148.19,131.83,129.34,128.58,125.30,122.94,121.82,121.68,103.05,102.29,44.79,32.56,22.63,19.14.HRMS(ESI):calcd for C22H19BrN3O[M+H]+:420.0711,found:420.0682。
实施例7
化合物E7(E)-2-(4-溴苯基)-N-(4-氟苯基)-6,7,8,9-四氢-4H-呋喃并[2,3-d]吡啶并[1,2-a]嘧啶-4-亚胺的制备:
在100mL两口瓶中,加入173mg,0.50mmol的2-(4-溴苯基)-6,7,8,9-四氢-4H-呋喃并[2,3-d]吡啶并[1,2-a]嘧啶-4-酮,再加入30mL无水二氯甲烷,并进行惰性气体保护,在温度0℃条件下,滴加58μL,0.55mmol 2-甲氧基吡啶,滴加168μL,1.0mmol三氟甲磺酸酐,30min后加入111mg,1.0mmol 4-氟苯胺,10min后,升至室温继续反应1.5小时,加入饱和碳酸氢钠,用二氯甲烷萃取,无水硫酸钠干燥,浓缩,用200-300目的硅胶,体积比4:1的石油醚:乙酸乙酯进行洗脱,得到化合物E7(E)-2-(4-溴苯基)-N-(4-氟苯基)-6,7,8,9-四氢-4H-呋喃并[2,3-d]吡啶并[1,2-a]嘧啶-4-亚胺,产率:99%,黄色固体,m.p.242-243℃;
1H NMR(600MHz,Chloroform-d)δ7.45(d,J=8.5Hz,2H),7.34(d,J=8.5Hz,2H),7.07(t,J=8.6Hz,2H),6.85(dd,J=8.5,4.9Hz,2H),5.57(s,1H),4.11(t,J=6.2Hz,2H),2.99(t,J=6.7Hz,2H),2.06(p,J=6.2Hz,2H),1.95(p,J=6.6Hz,2H).13C NMR(151MHz,CDCl3)δ161.11,159.95,158.35,157.25,148.98,148.37,131.90,128.45,125.36,122.82,122.77,121.87,116.01,115.86,102.74,102.16,44.78,32.56,22.63,19.11.HRMS(ESI):calcd for C22H18BrFN3O[M+H]+:438.0617,found:438.0588。
实施例8
化合物E8(E)-2-(4-溴苯基)-N-(4-氯苯基)-6,7,8,9-四氢-4H-呋喃并[2,3-d]吡啶并[1,2-a]嘧啶-4-亚胺的制备:
在100mL两口瓶中,加入173mg,0.50mmol的2-(4-溴苯基)-6,7,8,9-四氢-4H-呋喃并[2,3-d]吡啶并[1,2-a]嘧啶-4-酮,再加入30mL无水二氯甲烷,并进行惰性气体保护,在温度0℃条件下,滴加58μL,0.55mmol 2-甲氧基吡啶,滴加168μL,1.0mmol三氟甲磺酸酐,30min后加入128mg,1.0mmol 4-氯苯胺,10min后,升至室温继续反应1.5小时,加入饱和碳酸氢钠,用二氯甲烷萃取,无水硫酸钠干燥,浓缩,用200-300目的硅胶,体积比4:1的石油醚:乙酸乙酯进行洗脱,得到化合物E8(E)-2-(4-溴苯基)-N-(4-氯苯基)-6,7,8,9-四氢-4H-呋喃并[2,3-d]吡啶并[1,2-a]嘧啶-4-亚胺,产率:99%,黄色固体,m.p.238-239℃;
1H NMR(600MHz,Chloroform-d)δ7.46(d,J=8.5Hz,2H),7.34(dd,J=17.8,8.4Hz,4H),6.85(d,J=8.4Hz,2H),5.66(s,1H),4.10(t,J=6.2Hz,2H),2.99(t,J=6.7Hz,2H),2.06(p,J=6.2Hz,2H),1.95(p,J=6.6Hz,2H).13C NMR(151MHz,CDCl3)δ161.15,157.27,149.25,148.55,131.92,129.32,128.39,127.82,125.43,123.11,121.95,102.68,102.13,44.82,32.55,22.61,19.09.HRMS(ESI):calcd for C22H18BrClN3O[M+H]+:454.0322,found:454.0291。
实施例9
化合物E9(E)-N,2-双(4-溴苯基)-6,7,8,9-四氢-4H-呋喃并[2,3-d]吡啶并[1,2-a]嘧啶-4-亚胺的制备:
在100mL两口瓶中,加入173mg,0.50mmol的2-(4-溴苯基)-6,7,8,9-四氢-4H-呋喃并[2,3-d]吡啶并[1,2-a]嘧啶-4-酮,再加入30mL无水二氯甲烷,并进行惰性气体保护,在温度0℃条件下,滴加58μL,0.55mmol 2-甲氧基吡啶,滴加168μL,1.0mmol三氟甲磺酸酐,30min后加入172mg,1.0mmol 4-溴苯胺,10min后,升至室温继续反应1.5小时,加入饱和碳酸氢钠,用二氯甲烷萃取,无水硫酸钠干燥,浓缩,用200-300目的硅胶,体积比4:1的石油醚:乙酸乙酯进行洗脱,得到化合物E9(E)-N,2-双(4-溴苯基)-6,7,8,9-四氢-4H-呋喃并[2,3-d]吡啶并[1,2-a]嘧啶-4-亚胺,产率:99%,黄色固体,m.p.236-237℃;
1H NMR(600MHz,Chloroform-d)δ7.46(d,J=8.5Hz,4H),7.36(d,J=8.5Hz,2H),6.80(d,J=8.4Hz,2H),5.67(s,1H),4.10(t,J=6.1Hz,2H),2.99(t,J=6.7Hz,2H),2.06(p,J=6.1Hz,2H),1.95(p,J=6.6Hz,2H).13C NMR(151MHz,CDCl3)δ161.16,157.27,149.73,148.56,148.44,132.25,131.93,128.38,125.44,123.61,121.97,115.36,102.66,102.12,44.83,32.55,22.61,19.09.HRMS(ESI):calcd for C22H18Br2N3O[M+H]+:497.9817,found:497.9779。
实施例10
化合物E10(E)-2-(4-溴苯基)-N-(4-(三氟甲基)苯基)-6,7,8,9-四氢-4H-呋喃并[2,3-d]吡啶并[1,2-a]嘧啶-4-亚胺的制备:
在100mL两口瓶中,加入173mg,0.50mmol的2-(4-溴苯基)-6,7,8,9-四氢-4H-呋喃并[2,3-d]吡啶并[1,2-a]嘧啶-4-酮,再加入30mL无水二氯甲烷,并进行惰性气体保护,在温度0℃条件下,滴加58μL,0.55mmol 2-甲氧基吡啶,滴加168μL,1.0mmol三氟甲磺酸酐,30min后加入126μL,1.0mmol 4-三氟甲基苯胺,10min后,升至室温继续反应1.5小时,加入饱和碳酸氢钠,用二氯甲烷萃取,无水硫酸钠干燥,浓缩,用200-300目的硅胶,体积比4:1的石油醚:乙酸乙酯进行洗脱,得到化合物E10(E)-2-(4-溴苯基)-N-(4-(三氟甲基)苯基)-6,7,8,9-四氢-4H-呋喃并[2,3-d]吡啶并[1,2-a]嘧啶-4-亚胺,产率:85%,黄色固体,m.p.235-236℃;
1H NMR(600MHz,Chloroform-d)δ7.62(d,J=7.9Hz,2H),7.45(d,J=8.5Hz,2H),7.31(d,J=8.5Hz,2H),7.00(d,J=8.1Hz,2H),5.56(s,1H),4.13(t,J=5.7Hz,2H),3.01(t,J=6.6Hz,2H),2.12–2.04(m,2H),1.97(p,J=6.5Hz,2H).13C NMR(151MHz,CDCl3)δ161.22,157.31,154.10,148.77,148.30,131.95,128.26,126.50,125.37,124.84,124.62,123.80,122.07,121.99,102.40,102.08,44.91,32.55,22.60,19.09.HRMS(ESI):calcdfor C23H18BrF3N3O[M+H]+:488.0585,found:488.0547。
实施例11
合物F1(E)-9-亚苄基-2-(4-氟苯基)-6,7,8,9-四氢-4H-呋喃并[2,3-d]吡啶并[1,2-a]嘧啶-4-酮的制备:
在100mL两口瓶中,加入142mg,0.50mmol的2-(4-氟苯基)-6,7,8,9-四氢-4H-呋喃并[2,3-d]吡啶并[1,2-a]嘧啶-4-酮,加入255μL,2.50mmol苯甲醛类,加入100mg,2.50mmol氢氧化钠,再加入30mL乙醇,加热回流,通过TLC监测反应,直至反应完成,浓缩反应液,用饱和食盐水洗涤,无水硫酸钠干燥,用乙酸乙酯萃取,再浓缩,用200-300目的硅胶,体积比4:1的石油醚:乙酸乙酯进行洗脱,得到化合物F1(E)-9-亚苄基-2-(4-氟苯基)-6,7,8,9-四氢-4H-呋喃并[2,3-d]吡啶并[1,2-a]嘧啶-4-酮,产率:92%,红色固体,m.p.234-235℃;
1H NMR(400MHz,Chloroform-d)δ8.26(s,1H),7.81–7.75(m,2H),7.51–7.41(m,4H),7.39–7.33(m,1H),7.19–7.09(m,2H),7.07(s,1H),4.22–4.17(m,2H),3.01–2.94(m,2H),2.04(p,J=6.2Hz,2H).13C NMR(151MHz,CDCl3)δ163.73,163.42,162.08,159.00,153.10,151.75,136.08,135.97,130.09,129.14,128.56,128.53,126.38,126.32,125.89,116.15,116.00,106.82,100.47,42.67,25.87,21.96.HRMS(ESI):calcd for C23H18FN2O2[M+H]+:373.1352,found:373.1320。
实施例12
化合物F2(E)-2-(4-氟苯基)-9-(3-甲氧基亚苄基)-6,7,8,9-四氢-4H-呋喃并[2,3-d]吡啶并[1,2-a]嘧啶-4-酮的制备:
在100mL两口瓶中,加入142mg,0.50mmol的2-(4-氟苯基)-6,7,8,9-四氢-4H-呋喃并[2,3-d]吡啶并[1,2-a]嘧啶-4-酮,加入340mg,2.50mmol 3-甲氧基苯甲醛,加入100mg,2.50mmol氢氧化钠,再加入30mL乙醇,加热回流,通过TLC监测反应,直至反应完成,浓缩反应液,用饱和食盐水洗涤,无水硫酸钠干燥,用乙酸乙酯萃取,再浓缩,用200-300目的硅胶,体积比4:1的石油醚:乙酸乙酯进行洗脱,得到化合物F2(E)-2-(4-氟苯基)-9-(3-甲氧基亚苄基)-6,7,8,9-四氢-4H-呋喃并[2,3-d]吡啶并[1,2-a]嘧啶-4-酮,产率:48%,红色固体,m.p.191-193℃;
1H NMR(400MHz,Chloroform-d)δ8.22(s,1H),7.82–7.73(m,2H),7.35(t,J=8.0Hz,1H),7.18–7.08(m,3H),7.07(d,J=8.7Hz,2H),7.01(s,1H),6.94–6.89(m,1H),4.22–4.14(m,2H),3.85(s,3H),2.96(t,J=5.5Hz,2H),2.03(p,J=6.3Hz,2H).13C NMR(101MHz,CDCl3)δ164.09,163.34,161.62,159.51,158.92,152.96,151.71,137.23,135.90,129.45,129.36,126.34,126.26,122.46,116.13,115.91,115.58,114.06,106.80,100.44,55.31,42.62,25.89,21.89.HRMS(ESI):calcd for C24H20FN2O3[M+H]+:403.1458,found:403.1435。
实施例13
化合物F3(E)-9-(3,4-二甲氧基亚苄基)-2-(4-氟苯基)-6,7,8,9-四氢-4H-呋喃并[2,3-d]吡啶并[1,2-a]嘧啶-4-酮的制备:
在100mL两口瓶中,加入142mg,0.50mmol的2-(4-氟苯基)-6,7,8,9-四氢-4H-呋喃并[2,3-d]吡啶并[1,2-a]嘧啶-4-酮,加入415mg,2.50mmol 3,4-二甲氧基苯甲醛,加入100mg,2.50mmol氢氧化钠,再加入30mL乙醇,加热回流,通过TLC监测反应,直至反应完成,浓缩反应液,用饱和食盐水洗涤,无水硫酸钠干燥,用乙酸乙酯萃取,再浓缩,用200-300目的硅胶,体积比4:1的石油醚:乙酸乙酯进行洗脱,得到化合物F3(E)-9-(3,4-二甲氧基亚苄基)-2-(4-氟苯基)-6,7,8,9-四氢-4H-呋喃并[2,3-d]吡啶并[1,2-a]嘧啶-4-酮,产率:82%,红色固体,m.p.191-193℃;
1H NMR(400MHz,Chloroform-d)δ8.20(s,1H),7.80–7.73(m,2H),7.16–7.09(m,3H),7.07–7.02(m,2H),6.93(d,J=8.4Hz,1H),4.21–4.16(m,2H),3.93(s,3H),3.92(s,3H),2.98(t,J=5.5Hz,2H),2.09–2.00(m,2H).13C NMR(151MHz,CDCl3)δ163.50,162.03,158.98,153.40,151.55,149.59,148.76,136.09,128.89,127.14,126.32,126.26,125.89,123.46,116.13,115.98,113.62,110.96,106.47,100.49,55.97,42.38,26.13,21.96.HRMS(ESI):calcd for C25H22FN2O4[M+H]+:433.1564,found:433.1537。
实施例14
化合物F4(E)-9-(3,5-二甲氧基亚苄基)-2-(4-氟苯基)-6,7,8,9-四氢-4H-呋喃并[2,3-d]吡啶并[1,2-a]嘧啶-4-酮的制备
在100mL两口瓶中,加入142mg,0.50mmol的2-(4-氟苯基)-6,7,8,9-四氢-4H-呋喃并[2,3-d]吡啶并[1,2-a]嘧啶-4-酮,加入415mg,2.50mmol 3,5-二甲氧基苯甲醛,加入100mg,2.50mmol氢氧化钠,再加入30mL乙醇,加热回流,通过TLC监测反应,直至反应完成,浓缩反应液,用饱和食盐水洗涤,无水硫酸钠干燥,用乙酸乙酯萃取,再浓缩,用200-300目的硅胶,体积比4:1的石油醚:乙酸乙酯进行洗脱,得到化合物F4(E)-9-(3,5-二甲氧基亚苄基)-2-(4-氟苯基)-6,7,8,9-四氢-4H-呋喃并[2,3-d]吡啶并[1,2-a]嘧啶-4-酮,产率:18%,红色固体,m.p.198-199℃;
1H NMR(400MHz,Chloroform-d)δ8.18(s,1H),7.76(ddd,J=8.1,5.0,2.4Hz,2H),7.18–7.08(m,2H),7.06(s,1H),6.62(d,J=2.2Hz,2H),6.47(t,J=2.2Hz,1H),4.20–4.15(m,2H),3.82(s,6H),2.96(t,J=5.5Hz,2H),2.03(p,J=6.2Hz,2H).13C NMR(101MHz,CDCl3)δ164.09,163.30,161.61,160.65,158.89,152.87,151.71,137.68,135.95,129.55,126.33,126.25,125.82,125.79,116.13,115.91,108.08,106.81,100.57,100.42,55.42,55.41,42.62,25.94,21.86.HRMS(ESI):calcd for C25H22FN2O4[M+H]+:433.1564,found:433.1536。
实施例15
化合物F5(E)-2-(4-氟苯基)-9-(3,4,5-三甲氧基亚苄基)-6,7,8,9-四氢-4H-呋喃并[2,3-d]吡啶并[1,2-a]嘧啶-4-酮的制备:
在100mL两口瓶中,加入142mg,0.50mmol的2-(4-氟苯基)-6,7,8,9-四氢-4H-呋喃并[2,3-d]吡啶并[1,2-a]嘧啶-4-酮,加入490mg,2.50mmol 3,4,5-二甲氧基苯甲醛,加入100mg,2.50mmol氢氧化钠,再加入30mL乙醇,加热回流,通过TLC监测反应,直至反应完成,浓缩反应液,用饱和食盐水洗涤,无水硫酸钠干燥,用乙酸乙酯萃取,再浓缩,用200-300目的硅胶,体积比4:1的石油醚:乙酸乙酯进行洗脱,得到化合物F5(E)-2-(4-氟苯基)-9-(3,4,5-三甲氧基亚苄基)-6,7,8,9-四氢-4H-呋喃并[2,3-d]吡啶并[1,2-a]嘧啶-4-酮,产率:31%,红色固体,m.p.231-232℃;
1H NMR(400MHz,Chloroform-d)δ8.19(s,1H),7.82–7.72(m,2H),7.18–7.08(m,3H),7.06(s,1H),6.73(s,2H),4.22–4.16(m,2H),3.90(d,J=2.9Hz,9H),3.00(t,J=6.3Hz,2H),2.05(p,J=6.3Hz,2H).13C NMR(101MHz,CDCl3)δ164.09,163.36,161.61,158.90,153.06,152.99,151.68,138.68,136.11,131.39,128.28,126.32,126.24,125.83,125.79,116.14,115.92,107.62,106.68,100.45,60.96,56.24,56.21,42.48,26.03,21.93.HRMS(ESI):calcd for C26H24FN2O5[M+H]+:463.1669,found:463.1633。
实施例16
化合物F6(E)-9-亚苄基-2-(4-溴苯基)-6,7,8,9-四氢-4H-呋喃并[2,3-d]吡啶并[1,2-a]嘧啶-4-酮的制备:
在100mL两口瓶中,加入173mg,0.50mmol的2-(4-溴苯基)-6,7,8,9-四氢-4H-呋喃并[2,3-d]吡啶并[1,2-a]嘧啶-4-酮,加入255μL,2.50mmol苯甲醛,加入100mg,2.50mmol氢氧化钠,再加入30mL乙醇,加热回流,通过TLC监测反应,直至反应完成,浓缩反应液,用饱和食盐水洗涤,无水硫酸钠干燥,用乙酸乙酯萃取,再浓缩,用200-300目的硅胶,体积比4:1的石油醚:乙酸乙酯进行洗脱,得到化合物F6(E)-9-亚苄基-2-(4-溴苯基)-6,7,8,9-四氢-4H-呋喃并[2,3-d]吡啶并[1,2-a]嘧啶-4-酮,产率:99%,红色固体,m.p.237-239℃.1HNMR(400MHz,Chloroform-d)δ8.26(s,1H),7.69–7.62(m,2H),7.59–7.54(m,2H),7.54–7.30(m,5H),7.13(s,1H),4.21–4.16(m,2H),3.00–2.93(m,2H),2.11–1.99(m,2H).13C NMR(101MHz,CDCl3)δ163.45,158.86,153.29,151.44,140.03,136.20,135.89,132.06,130.06,128.49,127.17,125.82,123.53,122.57,106.73,101.34,42.63,25.82,21.90.HRMS(ESI):calcd for C23H18BrN2O2[M+H]+:433.0522,found:433.0519。
实施例17
化合物F7(E)-2-(4-溴苯基)-9-(3-甲氧基亚苄基)-6,7,8,9-四氢-4H-呋喃并[2,3-d]吡啶并[1,2-a]嘧啶-4-酮的制备
在100mL两口瓶中,加入173mg,0.50mmol的2-(4-溴苯基)-6,7,8,9-四氢-4H-呋喃并[2,3-d]吡啶并[1,2-a]嘧啶-4-酮,加入340mg,2.50mmol 3-甲氧基苯甲醛,加入100mg,2.50mmol氢氧化钠,再加入30mL乙醇,加热回流,通过TLC监测反应,直至反应完成,浓缩反应液,用饱和食盐水洗涤,无水硫酸钠干燥,用乙酸乙酯萃取,再浓缩,用200-300目的硅胶,体积比4:1的石油醚:乙酸乙酯进行洗脱,得到化合物F7(E)-2-(4-溴苯基)-9-(3-甲氧基亚苄基)-6,7,8,9-四氢-4H-呋喃并[2,3-d]吡啶并[1,2-a]嘧啶-4-酮,产率:38%,红色固体,m.p.180-181℃;
1H NMR(400MHz,Chloroform-d)δ8.22(d,J=2.1Hz,1H),7.67–7.62(m,2H),7.58–7.53(m,2H),7.34(t,J=8.0Hz,1H),7.12(s,1H),7.09–7.05(m,1H),7.00(t,J=2.1Hz,1H),6.93–6.88(m,1H),4.21–4.14(m,2H),3.84(s,3H),3.00–2.92(m,2H),2.08–1.98(m,2H).13C NMR(101MHz,CDCl3)δ163.41,159.50,158.84,153.20,151.44,137.19,136.05,129.30,128.37,122.57,106.75,101.34,55.31,42.62,25.88,21.86.HRMS(ESI):calcdfor C24H20BrN2O3[M+H]+:463.0657,found:463.0624。
实施例18
化合物F8(E)-2-(4-溴苯基)-9-(3,4-二甲氧基亚苄基)-6,7,8,9-四氢-4H-呋喃并[2,3-d]吡啶并[1,2-a]嘧啶-4-酮的制备:
在100mL两口瓶中,加入173mg,0.50mmol的2-(4-溴苯基)-6,7,8,9-四氢-4H-呋喃并[2,3-d]吡啶并[1,2-a]嘧啶-4-酮,加入415mg,2.50mmol 3,4-二甲氧基苯甲醛,加入100mg,2.50mmol氢氧化钠,再加入30mL乙醇,加热回流,通过TLC监测反应,直至反应完成,浓缩反应液,用饱和食盐水洗涤,无水硫酸钠干燥,用乙酸乙酯萃取,再浓缩,用200-300目的硅胶,体积比4:1的石油醚:乙酸乙酯进行洗脱,得到化合物F8(E)-2-(4-溴苯基)-9-(3,4-二甲氧基亚苄基)-6,7,8,9-四氢-4H-呋喃并[2,3-d]吡啶并[1,2-a]嘧啶-4-酮,产率:19%,红色固体,m.p.201-202℃;
1H NMR(400MHz,Chloroform-d)δ8.21(s,1H),7.66(d,J=8.5Hz,2H),7.56(d,J=8.6Hz,2H),7.16–7.11(m,2H),7.04(d,J=1.8Hz,1H),6.94(d,J=8.4Hz,1H),4.22–4.17(m,2H),3.94(s,3H),3.92(s,3H),2.99(t,J=5.5Hz,2H),2.10–2.01(m,2H).13C NMR(101MHz,CDCl3)δ163.55,158.89,153.61,151.27,149.60,148.73,136.25,132.05,128.83,128.43,127.04,125.78,123.45,122.51,113.60,110.94,106.40,101.37,55.96,55.92,42.36,26.09,21.92.HRMS(ESI):calcd for C25H22BrN2O4[M+H]+:493.0763,found:493.0730。
实施例19
化合物F9(E)-2-(4-溴苯基)-9-(3,5-二甲氧基亚苄基)-6,7,8,9-四氢-4H-呋喃并[2,3-d]吡啶并[1,2-a]嘧啶-4-酮的制备:
在100mL两口瓶中,加入173mg,0.50mmo)的2-(4-溴苯基)-6,7,8,9-四氢-4H-呋喃并[2,3-d]吡啶并[1,2-a]嘧啶-4-酮,加入415mg,2.50mmol 3,5-二甲氧基苯甲醛,加入100mg,2.50mmol氢氧化钠,再加入30mL乙醇,加热回流,通过TLC监测反应,直至反应完成,浓缩反应液,用饱和食盐水洗涤,无水硫酸钠干燥,用乙酸乙酯萃取,再浓缩,用200-300目的硅胶,体积比4:1的石油醚:乙酸乙酯进行洗脱,得到化合物F9(E)-2-(4-溴苯基)-9-(3,5-二甲氧基亚苄基)-6,7,8,9-四氢-4H-呋喃并[2,3-d]吡啶并[1,2-a]嘧啶-4-酮,产率:22%,红色固体,m.p.220-221℃;
1H NMR(400MHz,Chloroform-d)δ8.19(s,1H),7.66(d,J=8.5Hz,2H),7.56(d,J=8.5Hz,2H),7.13(s,1H),6.62(d,J=2.2Hz,2H),6.47(t,J=2.2Hz,1H),4.20–4.15(m,2H),3.83(s,6H),2.99–2.93(m,2H),2.04(q,J=6.5,5.9Hz,2H).13C NMR(151MHz,CDCl3)δ163.45,160.70,158.91,153.19,151.53,137.69,136.20,132.12,129.56,128.42,125.87,122.65,108.14,107.34,106.83,101.39,100.64,55.46,42.67,25.96,21.88.HRMS(ESI):calcd for C25H22BrN2O4[M+H]+:493.0763,found:493.0732。
实施例20
化合物F10(E)-2-(4-溴苯基)-9-(3,4,5-三甲氧基亚苄基)-6,7,8,9-四氢-4H-呋喃并[2,3-d]吡啶并[1,2-a]嘧啶-4-酮的制备:
在100mL两口瓶中,加入173mg,0.50mmol的2-(4-溴苯基)-6,7,8,9-四氢-4H-呋喃并[2,3-d]吡啶并[1,2-a]嘧啶-4-酮,加入490mg,2.50mmol 3,4,5-二甲氧基苯甲醛,加入100mg,2.50mmo)氢氧化钠,再加入30mL乙醇,加热回流,通过TLC监测反应,直至反应完,浓缩反应液,用饱和食盐水洗涤,无水硫酸钠干燥,用乙酸乙酯萃取,再浓缩,用200-300目的硅胶,体积比4:1的石油醚:进行洗脱,得到化合物F10(E)-2-(4-溴苯基)-9-(3,4,5-三甲氧基亚苄基)-6,7,8,9-四氢-4H-呋喃并[2,3-d]吡啶并[1,2-a]嘧啶-4-酮,产率:15%,红色固体,m.p.250-251℃;
1H NMR(400MHz,Chloroform-d)δ8.21(s,1H),7.66(d,J=8.6Hz,2H),7.57(d,J=8.5Hz,2H),7.14(s,1H),6.73(s,1H),6.61(s,1H),4.22–4.17(m,2H),3.90(d,J=3.0Hz,6H),3.87(s,3H),3.03–2.97(m,2H),2.10–2.02(m,2H).13C NMR(101MHz,CDCl3)δ163.55,158.81,153.48,152.97,151.28,140.00,135.76,132.24,132.06,128.43,127.36,125.77,122.98,122.51,106.53,104.38,101.48,60.98,56.24,56.20,42.40,24.49,21.35.HRMS(ESI):calcd for C26H24BrN2O5[M+H]+:523.0869,found:523.0833。
实施例21
化合物G1(E)-2-(4-氯苯基)-1-甲基-N-苯基-6,7,8,9-四氢吡啶并[1,2-a]吡咯并[2,3-d]嘧啶-4(1H)-亚胺的制备:
在100mL两口瓶中,加入157mg,0.50mmol的2-(4-氯苯基)-1-甲基-6,7,8,9-四氢吡啶并[1,2-a]吡咯并[2,3-d]嘧啶-4(1H)-酮,再加入30mL无水二氯甲烷,并进行惰性气体保护,在温度0℃条件下,滴加58μL,0.55mmol 2-甲氧基吡啶和168μL,1.0mmol三氟甲磺酸酐,30min后加入91μL,1.0mmol苯胺,在温度0℃条件下保持10min,升至室温继续反应1.5小时,加入饱和碳酸氢钠,用二氯甲烷萃取,无水硫酸钠干燥,浓缩,用200-300目的硅胶,体积比4:1的石油醚:乙酸乙酯进行洗脱,得到化合物G1(E)-2-(4-氯苯基)-1-甲基-N-苯基-6,7,8,9-四氢吡啶并[1,2-a]吡咯并[2,3-d]嘧啶-4(1H)-亚胺,产率:99%,黄色固体,m.p.281-283℃;
1H NMR(400MHz,Chloroform-d)δ7.32–7.27(m,3H),7.26(d,J=1.7Hz,1H),7.16–7.11(m,2H),7.06–7.00(m,1H),6.95–6.90(m,2H),5.10(s,1H),4.16(t,J=6.2Hz,2H),3.61(s,3H),2.95(t,J=6.7Hz,2H),2.03(p,J=6.1Hz,2H),1.93(p,J=6.4Hz,2H).13C NMR(101MHz,CDCl3)δ153.96,151.70,148.58,145.48,133.31,132.66,130.64,129.63,128.99,128.65,122.16,122.10,104.14,101.84,43.88,32.51,29.83,22.85,19.41.HRMS(ESI):calcd for C23H22ClN4[M+H]+:389.1533,found:389.1502。
实施例22
化合物G2(E)-2-(4-氯苯基)-N-(4-氟苯基)-1-甲基-6,7,8,9-四氢吡啶并[1,2-a]吡咯并[2,3-d]嘧啶-4(1H)-亚胺的制备:
在100mL两口瓶中,加入157mg,0.50mmol的2-(4-氯苯基)-1-甲基-6,7,8,9-四氢吡啶并[1,2-a]吡咯并[2,3-d]嘧啶-4(1H)-酮,再加入30mL无水二氯甲烷,并进行惰性气体保护,在温度0℃条件下,滴加58μL,0.55mmol 2-甲氧基吡啶和168μL,1.0mmol三氟甲磺酸酐,30min后加入111mg,1.0mmol 4-氟苯胺,在温度0℃条件下保持10min,升至室温继续反应1.5小时,加入饱和碳酸氢钠,用二氯甲烷萃取,无水硫酸钠干燥,浓缩,用200-300目的硅胶,体积比4:1的石油醚:乙酸乙酯进行洗脱,得到化合物G2(E)-2-(4-氯苯基)-N-(4-氟苯基)-1-甲基-6,7,8,9-四氢吡啶并[1,2-a]吡咯并[2,3-d]嘧啶-4(1H)-亚胺,产率:48%,黄色固体,m.p.240-242℃
1H NMR(400MHz,Chloroform-d)δ7.35–7.30(m,2H),7.18–7.13(m,2H),7.02–6.95(m,2H),6.90–6.83(m,2H),5.16(s,1H),4.14(t,J=6.2Hz,2H),2.95(t,J=6.7Hz,2H),2.03(p,J=6.5,6.1Hz,2H),1.93(p,J=6.5Hz,2H).13C NMR(101MHz,CDCl3)δ160.03,157.65,153.94,149.15,145.53,133.51,132.91,130.48,129.69,128.73,123.14,123.07,115.68,115.46,103.85,101.74,43.98,32.50,29.86,22.83,19.36.HRMS(ESI):calcd forC23H21ClFN4[M+H]+:407.1439,found:407.1408。
实施例23
化合物G3(E)-N,2-双(4-氯苯基)-1-甲基-6,7,8,9-四氢吡啶并[1,2-a]吡咯并[2,3-d]嘧啶-4(1H)-亚胺的制备:
在100mL两口瓶中,加入157mg,0.50mmol的2-(4-氯苯基)-1-甲基-6,7,8,9-四氢吡啶并[1,2-a]吡咯并[2,3-d]嘧啶-4(1H)-酮,再加入30mL无水二氯甲烷,并进行惰性气体保护,在温度0℃条件下,滴加58μL,0.55mmol 2-甲氧基吡啶和168μL,1.0mmol三氟甲磺酸酐,30min后加入128mg,1.0mmol 4-氯苯胺,在温度0℃条件下保持10min,升至室温继续反应1.5小时,加入饱和碳酸氢钠,用二氯甲烷萃取,无水硫酸钠干燥,浓缩,用200-300目的硅胶,体积比4:1的石油醚:乙酸乙酯进行洗脱,得到化合物G3(E)-N,2-双(4-氯苯基)-1-甲基-6,7,8,9-四氢吡啶并[1,2-a]吡咯并[2,3-d]嘧啶-4(1H)-亚胺,产率:68%,黄色固体,m.p.273-275℃;
1H NMR(400MHz,Chloroform-d)δ7.36–7.31(m,2H),7.27–7.21(m,2H),7.20–7.14(m,2H),6.89–6.83(m,2H),5.26(s,1H),4.13(t,J=6.2Hz,2H),3.61(s,3H),2.95(t,J=6.7Hz,2H),2.03(p,J=6.2Hz,2H),1.93(p,J=6.1Hz,2H).13C NMR(101MHz,CDCl3)δ153.94,150.35,148.65,145.53,133.57,133.00,130.46,129.77,128.97,128.75,126.96,123.41,103.86,101.67,43.93,32.49,29.85,22.82,19.37.HRMS(ESI):calcd forC23H21Cl2N4[M+H]+:423.1143,found:423.1115。
实施例24
化合物G4(E)-N-(4-溴苯基)-2-(4-氯苯基)-1-甲基-6,7,8,9-四氢吡啶并[1,2-a]吡咯并[2,3-d]嘧啶-4(1H)-亚胺的制备:
在100mL两口瓶中,加入157mg,0.50mmol的2-(4-氯苯基)-1-甲基-6,7,8,9-四氢吡啶并[1,2-a]吡咯并[2,3-d]嘧啶-4(1H)-酮,再加入30mL无水二氯甲烷,并进行惰性气体保护,在温度0℃条件下,滴加58μL,0.55mmol 2-甲氧基吡啶和168μL,1.0mmol三氟甲磺酸酐,30min后加入172mg,1.0mmol 4-溴苯胺,在温度0℃条件下保持10min,升至室温继续反应1.5小时,加入饱和碳酸氢钠,用二氯甲烷萃取,无水硫酸钠干燥,浓缩,用200-300目的硅胶,体积比4:1的石油醚:乙酸乙酯进行洗脱,得到化合物G4(E)-N-(4-溴苯基)-2-(4-氯苯基)-1-甲基-6,7,8,9-四氢吡啶并[1,2-a]吡咯并[2,3-d]嘧啶-4(1H)-亚胺,产率:99%,黄色固体,m.p.262-264℃;
1H NMR(400MHz,Chloroform-d)δ7.41–7.31(m,4H),7.20–7.15(m,2H),6.84–6.79(m,2H),5.27(s,1H),4.13(t,J=6.2Hz,2H),3.61(s,3H),2.95(t,J=6.7Hz,2H),2.02(p,J=6.2Hz,2H),1.93(p,J=6.1Hz,2H).13C NMR(101MHz,CDCl3)δ153.94,150.86,148.52,145.53,133.58,133.03,131.89,130.45,129.79,128.75,123.91,114.50,103.85,101.65,43.92,32.48,29.82,22.82,19.37.HRMS(ESI):calcd for C23H21BrClN4[M+H]+:467.0638,found:467.0607。
实施例25
化合物G5(E)-2-(4-氯苯基)-1-甲基-N-(4-(三氟甲基)苯基)-6,7,8,9-四氢吡啶并[1,2-a]吡咯并[2,3-d]嘧啶-4(1H)-亚胺的制备:
在100mL两口瓶中,加入157mg,0.50mmol的2-(4-氯苯基)-1-甲基-6,7,8,9-四氢吡啶并[1,2-a]吡咯并[2,3-d]嘧啶-4(1H)-酮,再加入30mL无水二氯甲烷,并进行惰性气体保护,在温度0℃条件下,滴加58μL,0.55mmol 2-甲氧基吡啶和168μL,1.0mmol三氟甲磺酸酐,30min后加入126μL,1.0mmol 4-三氟甲基苯胺,在温度0℃条件下保持10min,升至室温继续反应1.5小时,加入饱和碳酸氢钠,用二氯甲烷萃取,无水硫酸钠干燥,浓缩,用200-300目的硅胶,体积比4:1的石油醚:乙酸乙酯进行洗脱,得到化合物G5(E)-2-(4-氯苯基)-1-甲基-N-(4-(三氟甲基)苯基)-6,7,8,9-四氢吡啶并[1,2-a]吡咯并[2,3-d]嘧啶-4(1H)-亚胺,产率:61%,黄色固体,m.p.202-204℃;
1H NMR(400MHz,Chloroform-d)δ7.54(d,J=8.3Hz,2H),7.36–7.31(m,2H),7.18–7.13(m,2H),7.05(d,J=8.3Hz,2H),5.20(s,1H),4.19(t,J=6.2Hz,2H),2.99(t,J=6.7Hz,2H),2.05(p,J=6.1Hz,2H),1.95(p,J=6.5Hz,2H).13C NMR(101MHz,CDCl3)δ153.90,148.51,145.94,133.86,133.83,130.14,129.69,128.81,126.21,124.47,124.15,123.36,122.51,122.46,103.54,101.64,44.41,32.47,29.90,22.76,19.27.HRMS(ESI):calcd for C24H21ClF3N4[M+H]+:457.1407,found:457.1374。
实施例26
化合物G6(E)-2-(4-溴苯基)-1-甲基-N-苯基-1,6,7,8,9,10-六氢-4H-吡咯并[2',3':4,5]嘧啶并[1,2-a]氮杂-4-亚胺的制备:
在100mL两口瓶中,加入179mg,0.50mmol的2-(4-溴苯基)-1-甲基-1,6,7,8,9,10-六氢-4H-吡咯并[2',3':4,5]嘧啶并[1,2-a]氮杂-4-酮,再加入30mL无水二氯甲烷,并进行惰性气体保护,在温度0℃条件下,滴加58μL,0.55mmol 2-甲氧基吡啶和168μL,1.0mmol三氟甲磺酸酐,30min后加入91μL,1.0mmol苯胺,在温度0℃条件下保持10min,升至室温继续反应1.5小时,加入饱和碳酸氢钠,用二氯甲烷萃取,无水硫酸钠干燥,浓缩,用200-300目的硅胶,体积比4:1的石油醚:乙酸乙酯进行洗脱,得到化合物G6(E)-2-(4-溴苯基)-1-甲基-N-苯基-1,6,7,8,9,10-六氢-4H-吡咯并[2',3':4,5]嘧啶并[1,2-a]氮杂-4-亚胺,产率:45%,黄色固体,m.p.188-190℃;
1H NMR(400MHz,Chloroform-d)δ7.52–7.47(m,2H),7.38–7.32(m,2H),7.24–7.15(m,3H),7.09–7.04(m,2H),5.06(s,1H),4.65–4.59(m,2H),3.65(s,3H),3.21–3.15(m,2H),2.02–1.94(m,2H),1.88(s,4H).13C NMR(101MHz,CDCl3)δ158.76,149.66,147.17,131.92,131.84,130.24,130.13,129.80,129.35,125.63,124.65,122.72,118.80,103.64,101.73,47.18,37.63,30.06,29.04,27.23,25.31.HRMS(ESI):calcd for C24H24BrN4[M+H]+:447.1184,found:447.1150。
实施例27
化合物G7(E)-2-(4-溴苯基)-N-(4-氟苯基)-1-甲基-1,6,7,8,9,10-六氢-4H-吡咯并[2',3':4,5]嘧啶并[1,2-a]氮杂-4-亚胺的制备:
在100mL两口瓶中,加入179mg,0.50mmol的2-(4-溴苯基)-1-甲基-1,6,7,8,9,10-六氢-4H-吡咯并[2',3':4,5]嘧啶并[1,2-a]氮杂-4-酮,再加入30mL无水二氯甲烷,并进行惰性气体保护,在温度0℃条件下,滴加58μL,0.55mmol 2-甲氧基吡啶和168μL,1.0mmol三氟甲磺酸酐,30min后加入111mg,1.0mmol 4-氟苯胺,在温度0℃条件下保持10min,升至室温继续反应1.5小时,加入饱和碳酸氢钠,用二氯甲烷萃取,无水硫酸钠干燥,浓缩,用200-300目的硅胶,体积比4:1的石油醚:乙酸乙酯进行洗脱,得到化合物G7(E)-2-(4-溴苯基)-N-(4-氟苯基)-1-甲基-1,6,7,8,9,10-六氢-4H-吡咯并[2',3':4,5]嘧啶并[1,2-a]氮杂-4-亚胺,产率:72%,黄色固体,m.p.210-212℃;
1H NMR(400MHz,Chloroform-d)δ7.59–7.54(m,2H),7.37–7.30(m,2H),7.15–7.07(m,4H),5.12(s,1H),4.67–4.62(m,2H),3.70(s,3H),3.31–3.25(m,2H),2.10–2.03(m,2H),1.92(s,4H).13C NMR(101MHz,CDCl3)δ158.61,150.52,148.03,132.15,130.31,129.01,127.85,123.55,121.94,116.56,116.33,102.90,101.50,48.77,37.52,30.23,28.73,27.05,25.10.HRMS(ESI):calcd for C24H23BrFN4[M+H]+:465.1090,found:465.1056。
实施例28
化合物G8(E)-2-(4-溴苯基)-N-(4-氯苯基)-1-甲基-1,6,7,8,9,10-六氢-4H-吡咯并[2',3':4,5]嘧啶并[1,2-a]氮杂-4-亚胺的制备:
在100mL两口瓶中,加入179mg,0.50mmol的2-(4-溴苯基)-1-甲基-1,6,7,8,9,10-六氢-4H-吡咯并[2',3':4,5]嘧啶并[1,2-a]氮杂-4-酮,再加入30mL无水二氯甲烷,并进行惰性气体保护,在温度0℃条件下,滴加58μL,0.55mmol 2-甲氧基吡啶和168μL,1.0mmol三氟甲磺酸酐,30min后加入128mg,1.0mmol 4-氯苯胺,在温度0℃条件下保持10min,升至室温继续反应1.5小时,加入饱和碳酸氢钠,用二氯甲烷萃取,无水硫酸钠干燥,浓缩,用200-300目的硅胶,体积比4:1的石油醚:乙酸乙酯进行洗脱,得到化合物G8(E)-2-(4-溴苯基)-N-(4-氯苯基)-1-甲基-1,6,7,8,9,10-六氢-4H-吡咯并[2',3':4,5]嘧啶并[1,2-a]氮杂-4-亚胺,产率:61%,黄色固体,m.p.240-242℃;
1H NMR(400MHz,Chloroform-d)δ7.52–7.47(m,2H),7.25–7.21(m,2H),7.13–7.08(m,2H),6.87–6.82(m,2H),5.24(s,1H),4.59–4.53(m,2H),3.61(s,3H),3.06–3.01(m,2H),1.91–1.78(m,6H).13C NMR(101MHz,CDCl3)δ159.03,148.30,145.57,133.15,131.71,130.87,130.05,128.98,126.91,123.35,121.74,104.05,101.58,44.19,37.81,29.83,29.57,27.41,25.63.HRMS(ESI):calcd for C24H23BrClN4[M+H]+:481.0795,found:481.0763。
实施例29
化合物G9(E)-N,2-双(4-溴苯基)-1-甲基-1,6,7,8,9,10-六氢-4H-吡咯并[2',3':4,5]嘧啶并[1,2-a]氮杂-4-亚胺的制备:
在100mL两口瓶中,加入179mg,0.50mmol的2-(4-溴苯基)-1-甲基-1,6,7,8,9,10-六氢-4H-吡咯并[2',3':4,5]嘧啶并[1,2-a]氮杂-4-酮,再加入30mL无水二氯甲烷,并进行惰性气体保护,在温度0℃条件下,滴加58μL,0.55mmol 2-甲氧基吡啶和168μL,1.0mmol三氟甲磺酸酐,30min后加入172mg,1.0mmol 4-溴苯胺,在温度0℃条件下保持10min,升至室温继续反应1.5小时,加入饱和碳酸氢钠,用二氯甲烷萃取,无水硫酸钠干燥,浓缩,用200-300目的硅胶,体积比4:1的石油醚:乙酸乙酯进行洗脱,得到化合物G9(E)-N,2-双(4-溴苯基)-1-甲基-1,6,7,8,9,10-六氢-4H-吡咯并[2',3':4,5]嘧啶并[1,2-a]氮杂-4-亚胺,产率:77%,黄色固体,m.p.247-249℃;
1H NMR(400MHz,Chloroform-d)δ7.52–7.47(m,2H),7.40–7.35(m,2H),7.12–7.08(m,2H),6.83–6.78(m,2H),5.25(s,1H),4.59–4.53(m,2H),3.61(s,3H),3.06–3.01(m,2H),1.90–1.79(m,7H).13C NMR(101MHz,CDCl3)δ159.02,150.61,148.20,145.60,133.22,131.91,131.72,130.85,130.06,123.90,121.77,114.49,104.03,101.57,44.23,37.81,29.83,29.57,27.41,25.63.HRMS(ESI):calcd for C24H23Br2N4[M+H]+:525.0289,found:525.0256。
实施例30
化合物G10(E)-2-(4-溴苯基)-1-甲基-N-(4-(三氟甲基)苯基)-1,6,7,8,9,10-六氢-4H-吡咯并[2',3':4,5]嘧啶并[1,2-a]氮杂-4-亚胺的制备
在100mL两口瓶中,加入179mg,0.50mmol的2-(4-溴苯基)-1-甲基-1,6,7,8,9,10-六氢-4H-吡咯并[2',3':4,5]嘧啶并[1,2-a]氮杂-4-酮,再加入30mL无水二氯甲烷,并进行惰性气体保护,在温度0℃条件下,滴加58μL,0.55mmol 2-甲氧基吡啶和168μL,1.0mmol三氟甲磺酸酐,30min后加入126μL,1.0mmol 4-三氟甲基苯胺,在温度0℃条件下保持10min,升至室温继续反应1.5小时,加入饱和碳酸氢钠,用二氯甲烷萃取,无水硫酸钠干燥,浓缩,用200-300目的硅胶,体积比4:1的石油醚:乙酸乙酯进行洗脱,得到化合物G10(E)-2-(4-溴苯基)-1-甲基-N-(4-(三氟甲基)苯基)-1,6,7,8,9,10-六氢-4H-吡咯并[2',3':4,5]嘧啶并[1,2-a]氮杂-4-亚胺,产率:95%,黄色固体,m.p.188-190℃;
1H NMR(400MHz,Chloroform-d)δ7.52(d,J=8.3Hz,2H),7.50–7.46(m,2H),7.10–7.06(m,2H),6.99(d,J=8.2Hz,2H),5.19(s,1H),4.60–4.54(m,2H),3.62(s,3H),3.05(d,J=5.7Hz,2H),1.92–1.80(m,6H).13C NMR(101MHz,CDCl3)δ159.00,155.10,147.94,145.69,133.41,131.73,130.76,129.92,126.17,123.87,123.55,123.48,122.10,121.80,103.87,101.50,44.28,37.80,29.84,29.57,27.40,25.62.HRMS(ESI):calcd for C25H23BrF3N4[M+H]+:515.1058,found:515.1024。
实施例31
化合物H1 3-氯-2-(4-氯苯基)-1-甲基-6,7,8,9-四氢吡啶并[1,2-a]吡咯并[2,3-d]嘧啶-4(1H)-酮的制备:
在50mL单口瓶中,加入157mg,0.50mmol的2-(4-氯苯基)-1-甲基-6,7,8,9-四氢吡啶并[1,2-a]吡咯并[2,3-d]嘧啶-4(1H)-酮,加入10mL二氯甲烷,再加入74mg,0.55mmolN-氯代琥珀酰亚胺,加热回流,通过TLC监测反应,直至反应完成,浓缩反应液,用饱和食盐水洗涤,无水硫酸钠干燥,用乙酸乙酯萃取,再浓缩,用200-300目的硅胶,体积比2:1的石油醚:乙酸乙酯进行洗脱,得到化合物H1 3-氯-2-(4-氯苯基)-1-甲基-6,7,8,9-四氢吡啶并[1,2-a]吡咯并[2,3-d]嘧啶-4(1H)-酮,产率:77%,黄色固体,m.p.161-163℃;
1H NMR(400MHz,Benzene-d6)δ7.15–7.10(m,2H),7.04–6.98(m,2H),3.71(t,J=6.1Hz,2H),3.10(s,3H),2.49(t,J=6.6Hz,2H),1.22–1.09(m,4H).13C NMR(101MHz,C6D6)δ157.09,154.53,145.92,134.20,131.62,129.68,128.57,127.55,105.83,103.29,41.00,31.51,29.24,21.64,18.82.HRMS(ESI):calcd for C17H16Cl2N3O[M+H]+:348.0670,found:348.0644。
实施例32
化合物H2 3-溴-2-(4-氯苯基)-1-甲基-6,7,8,9-四氢吡啶并[1,2-a]吡咯并[2,3-d]嘧啶-4(1H)-酮的制备:
在50mL单口瓶中,加入157mg,0.50mmol的2-(4-氯苯基)-1-甲基-6,7,8,9-四氢吡啶并[1,2-a]吡咯并[2,3-d]嘧啶-4(1H)-酮,加入10mL二氯甲烷,再加入98mg,0.55mmolN-溴代琥珀酰亚胺,室温搅拌,通过TLC监测反应,直至反应完成,浓缩反应液,用饱和食盐水洗涤,无水硫酸钠干燥,用乙酸乙酯萃取,再浓缩,用200-300目的硅胶,体积比2:1的石油醚:乙酸乙酯进行洗脱,得到化合物H2 3-溴-2-(4-氯苯基)-1-甲基-6,7,8,9-四氢吡啶并[1,2-a]吡咯并[2,3-d]嘧啶-4(1H)-酮,产率:56%,黄色固体,m.p.135-136℃;
1H NMR(400MHz,Benzene-d6)δ7.14–7.10(m,2H),7.01–6.96(m,2H),3.70(t,J=6.1Hz,2H),3.10(s,3H),2.48(t,J=6.6Hz,2H),1.20–1.07(m,4H).13C NMR(101MHz,C6D6)δ157.28,154.38,146.57,134.31,131.84,131.56,128.52,128.28,104.58,90.88,41.03,31.52,29.47,21.63,18.80.HRMS(ESI):calcd for C17H16BrClN3O[M+H]+:392.0165,found:392.0138。
实施例33
化合物H3 2-(4-氯苯基)-3-碘-1-甲基-6,7,8,9-四氢吡啶并[1,2-a]吡咯并[2,3-d]嘧啶-4(1H)-酮的制备:
在50mL单口瓶中,加入157mg,0.50mmol的2-(4-氯苯基)-1-甲基-6,7,8,9-四氢吡啶并[1,2-a]吡咯并[2,3-d]嘧啶-4(1H)-酮,加入10mL二氯甲烷,再加入124mg,0.55mmolN-碘代琥珀酰亚胺,室温搅拌,通过TLC监测反应,直至反应完成,浓缩反应液,用饱和食盐水洗涤,无水硫酸钠干燥,用乙酸乙酯萃取,再浓缩,用200-300目的硅胶,体积比2:1的石油醚:乙酸乙酯进行洗脱,得到化合物H3 2-(4-氯苯基)-3-碘-1-甲基-6,7,8,9-四氢吡啶并[1,2-a]吡咯并[2,3-d]嘧啶-4(1H)-酮,产率:75%,黄色固体,m.p.168-169℃;
1H NMR(400MHz,Benzene-d6)δ7.13–7.09(m,2H),6.96–6.91(m,2H),3.68(t,J=6.1Hz,2H),3.11(s,3H),2.48(t,J=6.6Hz,2H),1.19–1.06(m,4H).13C NMR(101MHz,C6D6)δ157.61,154.06,147.47,135.44,134.44,132.15,129.65,128.52,106.63,56.76,41.08,31.58,29.87,21.63,18.79.HRMS(ESI):calcd for C17H16ClIN3O[M+H]+:440.0027,found:439.9998。
实施例34
化合物H4 2-(4-溴苯基)-3-氯-1-甲基-1,6,7,8,9,10-六氢-4H-吡咯并[2',3':4,5]嘧啶并[1,2-a]氮杂-4-酮的制备:
在50mL单口瓶中,加入179mg,0.50mmol的2-(4-溴苯基)-1-甲基-1,6,7,8,9,10-六氢-4H-吡咯并[2',3':4,5]嘧啶并[1,2-a]氮杂-4-酮,加入10mL二氯甲烷,再加入74mg,0.55mmolN-氯代琥珀酰亚胺,室温搅拌,通过TLC监测反应,直至反应完成,浓缩反应液,用饱和食盐水洗涤,无水硫酸钠干燥,用乙酸乙酯萃取,再浓缩,用200-300目的硅胶,体积比2:1的石油醚:乙酸乙酯进行洗脱,得到化合物H4 2-(4-溴苯基)-3-氯-1-甲基-1,6,7,8,9,10-六氢-4H-吡咯并[2',3':4,5]嘧啶并[1,2-a]氮杂-4-酮,产率:60%,黄色固体,m.p.224-226℃;
1H NMR(400MHz,Chloroform-d)δ7.64–7.59(m,2H),7.35–7.31(m,2H),4.41–4.35(m,2H),3.59(s,3H),3.06–3.00(m,2H),1.86–1.80(m,4H),1.79–1.72(m,2H).13C NMR(101MHz,CDCl3)δ159.70,157.90,145.84,131.89,131.83,130.62,127.74,122.98,105.81,102.78,41.99,37.65,30.13,29.59,27.88,25.45.HRMS(ESI):calcd forC18H18BrClN3O[M+H]+:406.0322,found:406.0295。
实施例35
化合物H5 3-溴-2-(4-溴苯基)-1-甲基-1,6,7,8,9,10-六氢-4H-吡咯并[2',3':4,5]嘧啶并[1,2-a]氮杂-4-酮的制备:
在50mL单口瓶中,加入179mg,0.50mmol的2-(4-溴苯基)-1-甲基-1,6,7,8,9,10-六氢-4H-吡咯并[2',3':4,5]嘧啶并[1,2-a]氮杂-4-酮,加入10mL二氯甲烷,再加入98mg,0.55mmolN-溴代琥珀酰亚胺,室温搅拌,通过TLC监测反应,直至反应完成,浓缩反应液,用饱和食盐水洗涤,无水硫酸钠干燥,用乙酸乙酯萃取,再浓缩,用200-300目的硅胶,体积比2:1的石油醚:乙酸乙酯进行洗脱,得到化合物H5 3-溴-2-(4-溴苯基)-1-甲基-1,6,7,8,9,10-六氢-4H-吡咯并[2',3':4,5]嘧啶并[1,2-a]氮杂-4-酮,产率:81%,黄色固体,m.p.208-209℃;
1H NMR(400MHz,Chloroform-d)δ7.64–7.59(m,2H),7.35–7.29(m,2H),4.41–4.35(m,2H),3.59(s,3H),3.06–3.01(m,2H),1.83(s,4H),1.79–1.73(m,2H).13C NMR(101MHz,CDCl3)δ159.61,158.04,146.42,132.52,132.10,131.85,131.82,128.46,123.12,104.03,90.89,42.08,37.65,30.38,29.60,27.86,25.45.HRMS(ESI):calcd for C18H18Br2N3O[M+H]+:449.9817,found:449.9785。
实施例36
化合物H6 2-(4-溴苯基)-3-碘-1-甲基-1,6,7,8,9,10-六氢-4H-吡咯并[2',3':4,5]嘧啶并[1,2-a]氮杂-4-酮的制备:
在50mL单口瓶中,加入179mg,0.50mmol的2-(4-溴苯基)-1-甲基-1,6,7,8,9,10-六氢-4H-吡咯并[2',3':4,5]嘧啶并[1,2-a]氮杂-4-酮,加入10mL二氯甲烷,再加入124mg,0.55mmolN-碘代琥珀酰亚胺,室温搅拌,通过TLC监测反应,直至反应完成,浓缩反应液,用饱和食盐水洗涤,无水硫酸钠干燥,用乙酸乙酯萃取,再浓缩,用200-300目的硅胶,体积比2:1的石油醚:乙酸乙酯进行洗脱,得到化合物H62-(4-溴苯基)-3-碘-1-甲基-1,6,7,8,9,10-六氢-4H-吡咯并[2',3':4,5]嘧啶并[1,2-a]氮杂-4-酮,产率:97%,黄色固体,m.p.209-211℃;
1H NMR(400MHz,Chloroform-d)δ7.65–7.60(m,2H),7.31–7.27(m,2H),4.41–4.35(m,2H),3.59(s,3H),3.06–3.00(m,2H),1.87–1.80(m,4H),1.79–1.73(m,2H).13C NMR(101MHz,CDCl3)δ159.34,158.33,147.45,136.41,132.40,131.86,131.81,129.84,123.26,106.05,56.91,42.16,37.75,30.72,29.63,27.88,25.49.HRMS(ESI):calcd forC18H18BrIN3O[M+H]+:497.9678,found:497.9641。
实施例37
将实施例1-36得到的任意一种三环嘧啶酮类化合物进行抗肿瘤活性筛选测定:
筛选方法:
MTT法检测细胞存活率:
实验过程:
将生长在对数生长期的细胞,吸去培养基,磷酸缓冲盐溶液洗1次,胰酶消化,加培养基终止,轻轻吹打,计数,以相应的细胞密度接种在96孔板中(100μL/孔),过夜培养,加化合物20μL/孔,每一化合物设浓度梯度,每一浓度设3复孔,CO2温度37℃培养箱内培养48小时,吸弃旧培养基,加入3-(4,5-二甲基噻唑-2)-2,5-二苯基四氮唑溴盐100μL,再继续培养2h,温度37℃孵育2小时后,使用MB酶标仪测570nm处的光吸收值(OD);
计算公式:
细胞活力百分比%=(化合物OD-空白OD/对照组OD-空白OD)×100%
细胞抑制率%=1-细胞活力%=【1-(化合物OD-空白OD/对照组OD-空白OD)】×100%,用graphpad,经公式拟合得IC50;
样品处理:
样品用二甲亚砜溶解,低温保存,二甲亚砜在最终体系中的浓度控制在不影响检测活性的范围之内;
数据处理及结果说明:
初筛选择单浓度条件下,例如单体化合物浓度50μM,提取物50μg/μL,对样品的活性进行测试;对于在一定条件下表现出较好活性的样品,例如抑制率大于50%,60%,70%的,选出一些样品进一步测试活性剂量依赖关系,即IC50值,通过样品活性对样品浓度进行非线性拟和得到,计算所用软件为Graphpad Prism 4,通常情况下,每个样品在测试中均设置复孔(n≥3),在结果中以标准偏差(Standard Deviation,SD)表示,通常情况下,每次测试均有已报道的化合物作为参照,所有数据都在知识能力范围内尽可能做到可信,精确,正确;
表 化合物E1-E10、F1-F10、G1-G10、H1-H6的抗肿瘤生物活性结果
从表中可以看出:根据生物活性的数据结果来看,这些化合物对MCF-7乳腺癌细胞的抑制作用并不明显,大多数化合物都没抑制活性表现,而对HeLa人宫颈癌细胞、HT-29人结肠癌细胞表现出较好的抑制活性,在合成的席夫碱化合物中,对比化合物E2,G6,G7可以看出,这一类型的化合物表现出较为突出的活性,IC50值相比其他化合物能达到个位数,而且苯环对位含有F的比不含F的活性更好,在克莱森缩合反应中得到的化合物F3和F5也表现出较好的抑制活性,其中化合物F3在苯环的5号位比化合物F5少一个甲氧基,仅此这样的变化将活性提高了一倍,使我们值得关注这一变化的结果。进一步可以发现,三环嘧啶类结构中,七元环结构化合物的肿瘤抑制活性普遍高于六元环结构化合物。总的来看,多数化合物对肿瘤具有较好的抑制活性,值得我们去进一步探究。
Claims (3)
1.一种三环嘧啶类衍生物,其特征在于该类衍生物的结构如下所示:
其中
化合物E-1为(E)-2-(4-氟苯基)-N-苯基-6,7,8,9-四氢-4H-呋喃并[2,3-d]吡啶并[1,2-a]嘧啶-4-亚胺;
化合物E-2为(E)-N,2-双(4-氟苯基)-6,7,8,9-四氢-4H-呋喃并[2,3-d]吡啶并[1,2-a]嘧啶-4-亚胺;
化合物E-3为(E)-N-(4-氯苯基)-2-(4-氟苯基)-6,7,8,9-四氢-4H-呋喃并[2,3-d]吡啶并[1,2-a]嘧啶-4-亚胺;
化合物E-4为(E)-N-(4-溴苯基)-2-(4-氟苯基)-6,7,8,9-四氢-4H-呋喃并[2,3-d]吡啶并[1,2-a]嘧啶-4-亚胺;
化合物E-5为(E)-2-(4-氟苯基)-N-(4-(三氟甲基)苯基)-6,7,8,9-四氢-4H-呋喃并[2,3-d]吡啶并[1,2-a]嘧啶-4-亚胺;
化合物E-6为(E)-2-(4-溴苯基)-N-苯基-6,7,8,9-四氢-4H-呋喃并[2,3-d]吡啶并[1,2-a]嘧啶-4-亚胺;
化合物E-7为(E)-2-(4-溴苯基)-N-(4-氟苯基)-6,7,8,9-四氢-4H-呋喃并[2,3-d]吡啶并[1,2-a]嘧啶-4-亚胺;
化合物E-8为(E)-2-(4-溴苯基)-N-(4-氯苯基)-6,7,8,9-四氢-4H-呋喃并[2,3-d]吡啶并[1,2-a]嘧啶-4-亚胺;
化合物E-9为(E)-N,2-双(4-溴苯基)-6,7,8,9-四氢-4H-呋喃并[2,3-d]吡啶并[1,2-a]嘧啶-4-亚胺;
化合物E-10为(E)-2-(4-溴苯基)-N-(4-(三氟甲基)苯基)-6,7,8,9-四氢-4H-呋喃并[2,3-d]吡啶并[1,2-a]嘧啶-4-亚胺;
化合物F-1为(E)-9-亚苄基-2-(4-氟苯基)-6,7,8,9-四氢-4H-呋喃并[2,3-d]吡啶并[1,2-a]嘧啶-4-酮;
化合物F-2为(E)-2-(4-氟苯基)-9-(3-甲氧基亚苄基)-6,7,8,9-四氢-4H-呋喃并[2,3-d]吡啶并[1,2-a]嘧啶-4-酮;
化合物F-3为(E)-9-(3,4-二甲氧基亚苄基)-2-(4-氟苯基)-6,7,8,9-四氢-4H-呋喃并[2,3-d]吡啶并[1,2-a]嘧啶-4-酮;
化合物F-4为(E)-9-(3,5-二甲氧基亚苄基)-2-(4-氟苯基)-6,7,8,9-四氢-4H-呋喃并[2,3-d]吡啶并[1,2-a]嘧啶-4-酮;
化合物F-5为(E)-2-(4-氟苯基)-9-(3,4,5-三甲氧基亚苄基)-6,7,8,9-四氢-4H-呋喃并[2,3-d]吡啶并[1,2-a]嘧啶-4-酮;
化合物F-6为(E)-9-亚苄基-2-(4-溴苯基)-6,7,8,9-四氢-4H-呋喃并[2,3-d]吡啶并[1,2-a]嘧啶-4-酮;
化合物F-7为(E)-2-(4-溴苯基)-9-(3-甲氧基亚苄基)-6,7,8,9-四氢-4H-呋喃并[2,3-d]吡啶并[1,2-a]嘧啶-4-酮;
化合物F-8为(E)-2-(4-溴苯基)-9-(3,4-二甲氧基亚苄基)-6,7,8,9-四氢-4H-呋喃并[2,3-d]吡啶并[1,2-a]嘧啶-4-酮;
化合物F-9为(E)-2-(4-溴苯基)-9-(3,5-二甲氧基亚苄基)-6,7,8,9-四氢-4H-呋喃并[2,3-d]吡啶并[1,2-a]嘧啶-4-酮;
化合物F-10为(E)-2-(4-溴苯基)-9-(3,4,5-三甲氧基亚苄基)-6,7,8,9-四氢-4H-呋喃并[2,3-d]吡啶并[1,2-a]嘧啶-4-酮;
化合物G-1为(E)-2-(4-氯苯基)-1-甲基-N-苯基-6,7,8,9-四氢吡啶并[1,2-a]吡咯并[2,3-d]嘧啶-4(1H)-亚胺;
化合物G-2为(E)-2-(4-氯苯基)-N-(4-氟苯基)-1-甲基-6,7,8,9-四氢吡啶并[1,2-a]吡咯并[2,3-d]嘧啶-4(1H)-亚胺;
化合物G-3为(E)-N,2-双(4-氯苯基)-1-甲基-6,7,8,9-四氢吡啶并[1,2-a]吡咯并[2,3-d]嘧啶-4(1H)-亚胺;
化合物G-4为(E)-N-(4-溴苯基)-2-(4-氯苯基)-1-甲基-6,7,8,9-四氢吡啶并[1,2-a]吡咯并[2,3-d]嘧啶-4(1H)-亚胺;
化合物G-5为(E)-2-(4-氯苯基)-1-甲基-N-(4-(三氟甲基)苯基)-6,7,8,9-四氢吡啶并[1,2-a]吡咯并[2,3-d]嘧啶-4(1H)-亚胺;
化合物G-6为(E)-2-(4-溴苯基)-1-甲基-N-苯基-1,6,7,8,9,10-六氢-4H-吡咯并[2',3':4,5]嘧啶并[1,2-a]氮杂-4-亚胺;
化合物G-7为(E)-2-(4-溴苯基)-N-(4-氟苯基)-1-甲基-1,6,7,8,9,10-六氢-4H-吡咯并[2',3':4,5]嘧啶并[1,2-a]氮杂-4-亚胺;
化合物G-8为(E)-2-(4-溴苯基)-N-(4-氯苯基)-1-甲基-1,6,7,8,9,10-六氢-4H-吡咯并[2',3':4,5]嘧啶并[1,2-a]氮杂-4-亚胺;
化合物G-9为(E)-N,2-双(4-溴苯基)-1-甲基-1,6,7,8,9,10-六氢-4H-吡咯并[2',3':4,5]嘧啶并[1,2-a]氮杂-4-亚胺;
化合物G-10为(E)-2-(4-溴苯基)-1-甲基-N-(4-(三氟甲基)苯基)-1,6,7,8,9,10-六氢-4H-吡咯并[2',3':4,5]嘧啶并[1,2-a]氮杂-4-亚胺;
化合物H-1为3-氯-2-(4-氯苯基)-1-甲基-6,7,8,9-四氢吡啶并[1,2-a]吡咯并[2,3-d]嘧啶-4(1H)-酮;
化合物H-2为3-溴-2-(4-氯苯基)-1-甲基-6,7,8,9-四氢吡啶并[1,2-a]吡咯并[2,3-d]嘧啶-4(1H)-酮;
化合物H-3为2-(4-氯苯基)-3-碘-1-甲基-6,7,8,9-四氢吡啶并[1,2-a]吡咯并[2,3-d]嘧啶-4(1H)-酮;
化合物H-4为2-(4-溴苯基)-3-氯-1-甲基-1,6,7,8,9,10-六氢-4H-吡咯并[2',3':4,5]嘧啶并[1,2-a]氮杂-4-酮;
化合物H-5为3-溴-2-(4-溴苯基)-1-甲基-1,6,7,8,9,10-六氢-4H-吡咯并[2',3':4,5]嘧啶并[1,2-a]氮杂-4-酮;
化合物H-6为2-(4-溴苯基)-3-碘-1-甲基-1,6,7,8,9,10-六氢-4H-吡咯并[2',3':4,5]嘧啶并[1,2-a]氮杂-4-酮。
2.一种如权利要求1所述的三环嘧啶酮类衍生物中的E1-E10、F1-F10、G1-G10和H1-H6在抗肿瘤药物中的用途。
3.一种如权利要求2所述的用途,其特征在于,三环嘧啶酮类衍生物中的E2、E3、F3、F5、H1、H5和H6对HeLa宫颈癌细胞有抑制活性;H1和H2对MCF-7乳腺癌细胞有抑制活性;E2、E3、F5、G1、G6、G7、H1、H3、H5和H6对HT-29人结肠癌细胞有抑制活性。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111496956.1A CN113943308B (zh) | 2021-12-09 | 2021-12-09 | 一种三环嘧啶类衍生物及用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111496956.1A CN113943308B (zh) | 2021-12-09 | 2021-12-09 | 一种三环嘧啶类衍生物及用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113943308A true CN113943308A (zh) | 2022-01-18 |
CN113943308B CN113943308B (zh) | 2023-11-10 |
Family
ID=79339034
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111496956.1A Active CN113943308B (zh) | 2021-12-09 | 2021-12-09 | 一种三环嘧啶类衍生物及用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113943308B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114478550A (zh) * | 2022-02-24 | 2022-05-13 | 中国科学院新疆理化技术研究所 | 一种三环吡咯并[2,3-d]嘧啶酮类衍生物及用途 |
Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993013664A2 (en) * | 1992-01-11 | 1993-07-22 | Schering Agrochemicals Limited | Biheterocyclic fungicidal compounds |
US20050027122A1 (en) * | 2003-02-12 | 2005-02-03 | Boehringer Ingelheim International Gmbh | Pyrrolidinohydrochinazolines |
US8729090B1 (en) * | 2011-10-05 | 2014-05-20 | The Florida State University Research Foundation, Inc. | Compositions and methods for inhibiting collagen production |
CN105017259A (zh) * | 2015-06-08 | 2015-11-04 | 浙江大学 | 含有三氟甲基的喹唑啉酮衍生物及其制备方法和应用 |
CN106749317A (zh) * | 2016-11-29 | 2017-05-31 | 中国科学院新疆理化技术研究所 | 一种氮杂环噻吩[2,3‑d]嘧啶酮苯磺酰胺类衍生物及用途 |
CN108299448A (zh) * | 2018-03-26 | 2018-07-20 | 长沙理工大学 | 一种合成4H-呋喃[2,3-d]嘧啶-4-酮衍生物的方法 |
WO2019119145A1 (en) * | 2017-12-21 | 2019-06-27 | Ontario Institute For Cancer Research (Oicr) | Tricyclic inhibitors of the bcl6 btb domain protein-protein interaction and uses thereof |
CN112724157A (zh) * | 2021-01-23 | 2021-04-30 | 中国科学院新疆理化技术研究所 | 二氢噁唑并[5,4-d]吡咯并[1,2-a]嘧啶-9(5H)-酮类衍生物及用途 |
CN112778333A (zh) * | 2021-01-23 | 2021-05-11 | 中国科学院新疆理化技术研究所 | 一种四氢噁唑并吡啶并氮氧杂酮类衍生物及其用途 |
CN112851692A (zh) * | 2021-01-23 | 2021-05-28 | 中国科学院新疆理化技术研究所 | 一种噁唑并[5,4-d]吡啶并[1,2-a]嘧啶酮类衍生物及其用途 |
CN113061138A (zh) * | 2021-03-26 | 2021-07-02 | 中国科学院新疆理化技术研究所 | 一种三氮唑[5,4-d]嘧啶酮三环类化合物及制备方法和用途 |
CN113105469A (zh) * | 2021-04-13 | 2021-07-13 | 中国科学院新疆理化技术研究所 | 一种三环呋喃并[2,3-d]嘧啶酮类化合物及用途 |
-
2021
- 2021-12-09 CN CN202111496956.1A patent/CN113943308B/zh active Active
Patent Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993013664A2 (en) * | 1992-01-11 | 1993-07-22 | Schering Agrochemicals Limited | Biheterocyclic fungicidal compounds |
US20050027122A1 (en) * | 2003-02-12 | 2005-02-03 | Boehringer Ingelheim International Gmbh | Pyrrolidinohydrochinazolines |
US8729090B1 (en) * | 2011-10-05 | 2014-05-20 | The Florida State University Research Foundation, Inc. | Compositions and methods for inhibiting collagen production |
CN105017259A (zh) * | 2015-06-08 | 2015-11-04 | 浙江大学 | 含有三氟甲基的喹唑啉酮衍生物及其制备方法和应用 |
CN106749317A (zh) * | 2016-11-29 | 2017-05-31 | 中国科学院新疆理化技术研究所 | 一种氮杂环噻吩[2,3‑d]嘧啶酮苯磺酰胺类衍生物及用途 |
WO2019119145A1 (en) * | 2017-12-21 | 2019-06-27 | Ontario Institute For Cancer Research (Oicr) | Tricyclic inhibitors of the bcl6 btb domain protein-protein interaction and uses thereof |
US20210053978A1 (en) * | 2017-12-21 | 2021-02-25 | Ontario Institute For Cancer Research (Oicr) | Tricyclic inhibitors of the bcl6 btb domain protein-protein interaction and uses thereof |
CN108299448A (zh) * | 2018-03-26 | 2018-07-20 | 长沙理工大学 | 一种合成4H-呋喃[2,3-d]嘧啶-4-酮衍生物的方法 |
CN112724157A (zh) * | 2021-01-23 | 2021-04-30 | 中国科学院新疆理化技术研究所 | 二氢噁唑并[5,4-d]吡咯并[1,2-a]嘧啶-9(5H)-酮类衍生物及用途 |
CN112778333A (zh) * | 2021-01-23 | 2021-05-11 | 中国科学院新疆理化技术研究所 | 一种四氢噁唑并吡啶并氮氧杂酮类衍生物及其用途 |
CN112851692A (zh) * | 2021-01-23 | 2021-05-28 | 中国科学院新疆理化技术研究所 | 一种噁唑并[5,4-d]吡啶并[1,2-a]嘧啶酮类衍生物及其用途 |
CN113061138A (zh) * | 2021-03-26 | 2021-07-02 | 中国科学院新疆理化技术研究所 | 一种三氮唑[5,4-d]嘧啶酮三环类化合物及制备方法和用途 |
CN113105469A (zh) * | 2021-04-13 | 2021-07-13 | 中国科学院新疆理化技术研究所 | 一种三环呋喃并[2,3-d]嘧啶酮类化合物及用途 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114478550A (zh) * | 2022-02-24 | 2022-05-13 | 中国科学院新疆理化技术研究所 | 一种三环吡咯并[2,3-d]嘧啶酮类衍生物及用途 |
CN114478550B (zh) * | 2022-02-24 | 2023-11-24 | 中国科学院新疆理化技术研究所 | 一种三环吡咯并[2,3-d]嘧啶酮类衍生物及用途 |
Also Published As
Publication number | Publication date |
---|---|
CN113943308B (zh) | 2023-11-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2005332339B2 (en) | Furanopyridine derivatives as ACK1 and Lck modulators | |
CN113061138B (zh) | 一种三氮唑[5,4-d]嘧啶酮三环类化合物及制备方法和用途 | |
CN101277689B (zh) | 噻唑并嘧啶类激酶抑制剂 | |
AU2014238443A1 (en) | MK2 inhibitors and uses thereof | |
EP3345906A1 (en) | 2-arylamino pyridine, pyridine or triazine derivative, preparation method and use thereof | |
CN113105469B (zh) | 一种三环呋喃并[2,3-d]嘧啶酮类化合物及用途 | |
BRPI0511239B1 (pt) | SUPORTE DE MÚLTIPLOS DISPOSITIVOS MESTRES DE DISEqC EM UM SISTEMA DE DISTRIBUIÇÃO DE VÍDEO | |
CN113943308B (zh) | 一种三环嘧啶类衍生物及用途 | |
CN112125911A (zh) | Cdk9抑制剂及其制备方法与应用 | |
CN116133666A (zh) | 一种硼酸酯衍生物及其用途 | |
CN109053594B (zh) | 1-(3,5-二甲氧基苯基)-3-(取代嘧啶-4-基)脲类化合物及其制备和应用 | |
CN114478549B (zh) | 一种吡唑并[3,4-d]吡咯(啶)并[1,2-a]嘧啶酮亚芳基类衍生物及其用途 | |
CN108341831B (zh) | 7H-[1,2,4]三唑[3,4-b][1,3,4]噻二嗪-苯腙型化合物 | |
CN113461661B (zh) | 6-(吡啶-3-基)喹唑啉-4(3h)-酮类衍生物及其制备和应用 | |
Mourad et al. | A Facile Synthesis of Novel Heterocyclic Compounds with Anticipated Antibacterial Activities Based on Coumarin Moiety | |
Deng et al. | Synthesis, Crystal Structure, and DFT Study of a New Derivative of Pyrido [2, 3-d] pyrimidine | |
CN113896716A (zh) | 一种放射性同位素碳-14双标记甲磺酸伏美替尼合成方法 | |
EP3915990A1 (en) | 4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-3,6-dihydropyridine-1-(2h)-carboxamide derivatives as limk and/or rock kinases inhibitors for use in the treatment of cancer | |
El-Gazzar et al. | A Simple Synthesis and Antimicrobial Activity of Sulfur-containing Poly-condensed Heterocyclic Derivatives from 1, 3-benzothiazole. | |
CN114478550B (zh) | 一种三环吡咯并[2,3-d]嘧啶酮类衍生物及用途 | |
CN102382064B (zh) | 喹唑酮衍生物及其制备方法和应用 | |
CN111533700B (zh) | 一种5-取代的尿嘧啶衍生物及其制备方法和应用 | |
KR20180096572A (ko) | 코판리십의 제조방법 | |
CN110357892A (zh) | 四氢嘧啶并[1,2-a]吲哚衍生物及其合成方法与应用 | |
CN111518078B (zh) | 一种含氨基吡啶的嘧啶类化合物及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |